Allele-specific splicing conversion oligonucleotides targeting false exons

Through splicing conversion oligonucleotides (SSO) binding to pre-mRNA in pseudoexon regions of specific genes, it promotes pseudoexon incorporation into mRNA, solving the difficulty of mutations outside exon splicing sites on RNA splicing. The prediction problem achieves specific regulation and treatment of pathogenic alleles.

CN119013399APending Publication Date: 2024-11-22SYDDANSK UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030631.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-06-29
Filing Date
2023-01-26
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively predict and regulate the effect of splicing regulatory sequence mutations outside exon splicing sites on RNA splicing, leading to diseases, and it is difficult to specifically target pathogenic alleles to avoid the impact on normal alleles.

Method used

Promote pseudoexon incorporation maturation by identifying and using splice-converting oligonucleotides (SSO) to bind to pre-mRNAs at the +9 to +39 regions downstream of the pseudoexon 5' splicing site of a specific gene, increasing pseudoexon maturation by identifying and using splice-converting oligonucleotides (SSOs). In mRNA, thereby regulating gene expression and using allelic-specific SNP to target pathogenic genes.

Benefits of technology

The specific splicing regulation of pathogenic genes is achieved, avoiding the impact on normal alleles, and enhancing the therapeutic potential of dysfunctional genes or pathogenic genes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013399A_ABST
    Figure CN119013399A_ABST
Patent Text Reader

Abstract

The present invention relates to a method of identifying a splice transition oligonucleotide (SSO) capable of modulating expression of a target protein in a cell by promoting incorporation of a pseudoexon into a mature mRNA when bound to pre-mRNA in the + 9 to + 39 region downstream of the 5'splice site of the pseudoexon. The invention also relates to the SSO obtained by said method and to the use thereof. In particular, the present invention relates to allele-specific splicing conversion oligonucleotides (SSOs).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to allele-specific splice switching oligonucleotides (SSOs) that can activate splicing of pseudoexons. In particular, SSOs are capable of promoting the inclusion of pseudoexons in mRNA transcripts of genes, such as in an allele-specific manner, thereby inhibiting the expression of functional gene products. In another aspect, the present invention relates to a method for identifying pseudoexons, for which it is possible to use SSOs to incorporate pseudoexons into mature mRNAs. Background Art

[0002] Newly synthesized eukaryotic mRNA molecules in the nucleus, also called primary transcripts or pre-mRNAs, are processed before or during transport to the cytoplasm for translation. Processing of pre-mRNA includes the addition of a 5' methylated cap and a poly(A) tail of approximately 200-250 nucleotides at the 3' end of the transcript.

[0003] Another step in mRNA processing is the splicing of pre-mRNA, which is part of the maturation of 90-95% of mammalian mRNA. Introns (or intervening sequences) are regions in the primary transcript that are not included in the coding sequence of the mature mRNA. Exons are regions of the primary transcript that remain in the mature mRNA when they reach the cytoplasm. Exons are spliced ​​together to form a mature mRNA sequence. Splicing occurs between splice sites that form a splice junction together. The splice site at the 5' end of the intron is often referred to as the "5' splice site" or "splice donor site", and the splice site at the 3' end of the intron is referred to as the "3' splice site" or "splice acceptor site". In splicing, the 3' end of the upstream exon is connected to the 5' end of the downstream exon. Therefore, unspliced ​​RNA (or pre-mRNA) has an exon / intron splice site at the 5' end of the intron and an intron / exon splice site at the 3' end of the intron. After introns are removed, exons are contiguous at (sometimes referred to as) exon / exon junctions or boundaries in the mature mRNA. Alternative splicing, defined as the splicing together of different combinations of exons or exon fragments, often results in the expression of multiple mature mRNA transcripts from a single gene.

[0004] Splicing of precursor mRNA (pre-mRNA) is an important step in eukaryotic gene expression, in which introns are removed through the activity of the spliceosome and the coding portion of the gene is spliced ​​together to produce functional mRNA. Pre-mRNA splicing is a highly controlled process, and it has been well established that mutations can affect splicing and produce aberrant transcripts. Correct mRNA splicing depends on regulatory sequences recognized by different factors of the spliceosome, as well as splicing regulatory factors. Splicing regulatory factors stimulate or inhibit exon recognition and splicing by sequence-specific binding to splicing regulatory sequences such as splicing enhancers and splicing silencers. Pre-mRNA splicing in eukaryotes is often associated with extensive alternative splicing to enrich their proteome. Alternative choice of splicing sites allows eukaryotes to regulate cell-type-specific gene expression, contributing to their functional diversification. Alternative splicing is a highly regulated process affected by splicing regulatory proteins, such as SR proteins or hnRNPs, which recognize splicing regulatory sequences, such as exonic splicing enhancers (ESEs) and exonic splicing silencers (ESSs) in exons, and intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs) in introns.

[0005] It is a well-known fact that exon mutations that create or eliminate existing splicing regulatory sequences other than splice site sequences often lead to mis-splicing of RNA, which can cause disease. However, it is difficult to predict which mutations affect splicing because not all exons are strictly dependent on splicing regulatory elements other than splice sites, and thus only a limited number of exons are susceptible to mutations in splicing regulatory sequences other than splice sites. Summary of the invention

[0006] The present invention relates to the identification of sequence parameters in genes comprising pseudoexons, which can be used to determine whether it is possible to incorporate pseudoexons into mature mRNA using splice switching oligonucleotides (SSOs). By incorporating pseudoexons into mature mRNA, the incorporation of pseudoexons can, for example, be used to inactivate, disrupt or alter the function of a functional product expressed by the gene (see also Example 1 and the corresponding figures and legends for more information). The present invention also relates to the (medical) use of such SSOs.

[0007] In one method of the present invention, the present team has identified a number of SNPs within the SSO binding region that allow allele-specific targeting. Allele-specific SSOs can be used to preferentially target pathogenic pre-mRNAs (from pathogenic alleles), while pre-mRNAs from "normally functioning" alleles are not affected (or are less affected). (See Example 13).

[0008] In another method of the present invention, the present invention team has identified SNPs within the splice site sequence of the pseudoexon, which allow pseudoexons to be incorporated allele-specifically in the mature RNA of only the pathogenic gene (rather than other "normal" genes on other alleles). In other words, when the MaxEnt score of the splice site in the pathogenic gene is increased compared to other alleles, allele-specific targeting is possible (see Examples 15-16).

[0009] Example 2 shows that the identified parameters are essential for identifying activatable pseudoexons (Table 1) and non-activatable pseudoexons (Table 2).

[0010] Example 3 presents data related to SMAD2 (see also Example 11).

[0011] Example 12 shows data related to RNF115.

[0012] Examples 4-11 and 13-14 show other examples of specific genes containing pseudoexons that can be activated (incorporated into mature mRNA).

[0013] Examples 13, 15 and 16 demonstrate allele-specific targeting.

[0014] Therefore, one object of the present invention relates to providing sequence parameters (criteria) that allow identification of binding sites of SSOs for incorporation of pseudoexons into mature mRNA.

[0015] Another object of the present invention is to provide SSOs that can promote the incorporation of pseudoexons into mature mRNA in vivo, thereby inactivating, disrupting or altering the native function of the gene.

[0016] Therefore, one aspect of the present invention relates to a method for identifying an SSO capable of regulating the expression and / or function of a target protein in a cell by promoting the incorporation of a pseudoexon into a mature mRNA when binding to a pre-mRNA in the region +9 to +39 downstream of the 5' splice site of the pseudoexon, the method comprising;

[0017] a) providing one or more gene sequences comprising one or more identified pseudoexons, such as in the form of a database or other storage means;

[0018] b) determining one or more gene sequences; if the pseudoexon meets the following criteria:

[0019] Pseudoexon length <160 nt;

[0020] Pseudoexon length > 30 nt;

[0021] ●The last 3 nt of the pseudoexon is different from TAG;

[0022] MaxEnt score of the donor splice site ≥ 4.33;

[0023] MaxEnt score of the donor splice site ≤ 10.06; and

[0024] The MaxEnt score of the receptor splice site is ≥3.63;

[0025] c) determining the position of the pseudo exon (3) downstream of the 5' splice site from +9 to

[0026] Does the +39 sequence region meet the following criteria:

[0027] Total pyrimidines ≤ 20;

[0028] Total thymidine bases ≤ 12;

[0029] Total thymidine bases ≥ 4;

[0030] Total guanine bases ≤ 12;

[0031] The maximum length of thymidine polymer is ≤ 4;

[0032] The maximum length of pyrimidine polymer is ≤10;

[0033] The minimum length of purine polymer is ≥ 3; and

[0034] The maximum number of guanine polymers with a length of at least 3 nt is ≤ 2;

[0035] Wherein, if one or more gene sequences meet the criteria according to item b) and item c), the +9 to +39 region downstream of the 5' splice site of the pseudo exon (3) is considered to be a target of the SSO, which is capable of hybridizing with the pre-mRNA (2) of the gene in the +9 to +39 region downstream of the 5' splice site of the pseudo exon (3) in vivo; and causing the pseudo exon (3) to become part of the mature mRNA to a greater extent compared to the corresponding pre-mRNA not contacted with the SSO (1);

[0036] as well as

[0037] Optionally, the SSO is prepared, optionally for use as a medicament.

[0038] The present invention also relates to a specifically identified SSO for use as a medicament. Thus, another aspect of the present invention relates to a composition comprising a splice switching oligonucleotide (SSO) for use as a medicament, the composition comprising

[0039] - A SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0040] o A nucleic acid according to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0041] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0042] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125, and 137-201;

[0043] or

[0044] - An SSO selected from the group consisting of:

[0045] o a nucleic acid according to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216; or

[0046] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216; or

[0047] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216;

[0048] The SSO is complementary or substantially complementary to a target pre-mRNA (encoding a functional protein that causes or affects a disease), and the target pre-mRNA comprises:

[0049] - Functionally disabling pseudoexons, including:

[0050] o 3' splice site at the 5' end; and

[0051] o 5' splice site at the 3' end;

[0052] wherein the SSO is complementary or substantially complementary to the target pre-RNA in the region +9 to +39 downstream of the 5' splice site of the pseudoexon;

[0053] Wherein, when the SSO hybridizes in vivo with the pre-mRNA in the +9 to +39 region downstream of the 5' splice site of the pseudo exon; the pseudo exon becomes part of the mature mRNA to a greater extent than the corresponding pre-mRNA not contacted with the SSO.

[0054] In yet another aspect, the present invention relates to

[0055] - A composition comprising an SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0056] o A nucleic acid according to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0057] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0058] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125, and 137-201;

[0059] or

[0060] - A composition comprising an SSO selected from the group consisting of:

[0061] - a nucleic acid according to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216; or

[0062] - Compared to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216, comprising 1

[0063] or 2 or 3 substituted nucleic acids; or

[0064] - has at least 90% affinity to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216

[0065] Nucleic acid sequences with sequence identity.

[0066] Another aspect of the present invention relates to a composition comprising a splice switching oligonucleotide (SSO) for use as a medicament, the composition comprising

[0067] - A SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0068] o a nucleic acid according to any one of SEQ ID NOs: 217-294;

[0069] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 217-294; or

[0070] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 217-294;

[0071] or

[0072] - An SSO selected from the group consisting of:

[0073] o a nucleic acid according to any one of SEQ ID NOs: 295-367; or

[0074] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 295-367; or

[0075] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 295-367;

[0076] wherein the SSO is complementary or substantially complementary to a target pre-mRNA, the target pre-mRNA comprising:

[0077] - Functionally disabling pseudoexons, including:

[0078] o 3' splice site at the 5' end; and

[0079] o 5' splice site at the 3' end;

[0080] The SSO is complementary or substantially complementary to the target pre-mRNA in the region +9 to +39 downstream of the 5' splice site of the pseudo exon.

[0081] The present invention can also be used to identify subjects who meet the criteria for pseudoexon inclusion therapy based on allele-specific SSOs. Therefore, one aspect of the present invention relates to a method for identifying subjects who may meet the criteria for pseudoexon inclusion therapy based on allele-specific SSOs of a dysfunctional gene or a pathogenic gene, the method comprising

[0082] - determining the presence or absence of heterozygosity in a pseudoexon of a dysfunctional gene or a disease-causing gene in a biological sample from the subject;

[0083] wherein if the subject is heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site, preferably in the 5' splice site, of the functionally disabling pseudoexon, then the subject may meet the criteria for allele-specific SSO-based pseudoexon inclusion treatment; or

[0084] wherein if the subject is not heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site of the functionally disabling pseudoexon, the subject may not meet criteria for allele-specific SSO-based pseudoexon inclusion treatment;

[0085] Wherein the SSO is complementary or substantially complementary to a target pre-mRNA of a dysfunctional gene or a disease-causing gene, the target pre-mRNA comprising:

[0086] - Functionally disabling pseudoexons, including:

[0087] o 3' splice site at the 5' end; and

[0088] o 5' splice site at the 3' end.

[0089] Another aspect of the present invention relates to a method for identifying a subject who may meet the criteria for SSO-based pseudoexon inclusion treatment of a dysfunctional gene or a pathogenic gene, the method comprising

[0090] - determining the presence or absence of a SNP in a pseudoexon of a dysfunctional gene or a disease-causing gene in a biological sample from the subject, which enables SSO-based pseudoexon inclusion therapy;

[0091] wherein if the subject has a sequence variation (SNP) at the 5' splice site and / or the 3' splice site, preferably the 5' splice site, of the functionally disabling pseudoexon, then the subject may meet the criteria for SSO-based pseudoexon inclusion treatment; or

[0092] wherein if the subject does not have a sequence variation (SNP) at the 5' splice site and / or the 3' splice site of the functionally disabling pseudoexon, the subject may not meet the criteria for SSO-based pseudoexon inclusion therapy;

[0093] o Wherein the SSO is complementary or substantially complementary to a target pre-mRNA of a dysfunctional gene or a disease-causing gene, wherein the target pre-mRNA comprises:

[0094] - Functionally disabling pseudoexons, including:

[0095] o 3' splice site at the 5' end; and

[0096] o 5' splice site at the 3' end. BRIEF DESCRIPTION OF THE DRAWINGS

[0097] Figure 1

[0098] FIG. 1 shows a schematic diagram of gene expression regulation by SSO according to the present invention. Figure 1A ): The sweet spot region is identified in the intron part of the pre-mRNA, which is the region +9 to +39 nucleotides downstream of the 5' splice site of the pseudo exon that meets the criteria of the present invention. Figure 1B ): By using an SSO that is complementary to the optimal site region of a pseudoexon that meets the criteria, pseudoexon inclusion in the mRNA transcript can be activated and increased. Pseudoexon inclusion in mRNA will modulate gene expression at the mRNA level or protein level through mislocalization, destabilization, degradation or alteration of mRNA or protein function.

[0099] Figure 2

[0100] Figure 2 Schematic showing how RNA sequencing data can be used to detect double junctions of in vivo splicing for the empirical detection of pseudo exons that are included at low levels in endogenous transcripts.

[0101] After mapping to the human genome, reads are filtered to retain only fragments containing at least two splice junctions. The splice junctions of the entire fragment are then assembled into exon structures, leaving an unmapped gap of up to 100 bp between reads in the fragment. Exons are then classified using known exon annotations to identify pseudoexons contained within introns. New pseudoexons that may be candidates for activation by SSO binding to the optimal site region can be identified by 14 criteria, after which highly therapeutically relevant pseudoexons can be identified in genes where downregulation or altered expression of the functional gene product is medically relevant.

[0102] Figure 3

[0103] LINGO2 pseudoexon inclusion inhibits the growth and proliferation of glioblastoma cells. (A) RT-PCR analysis of LINGO2 pseudoexon splicing in U251 cells transfected with LINGO2 pseudoexon +11SSO and non-targeting SSO control. The upper band includes the pseudoexon, which is activated by transfection of +11SSO. (B) Cell proliferation assay, showing growth curves (cell confluency relative to time post-transfection) of U251 cells transfected with different concentrations of LINGO2+11SSO and a non-targeting SSO control. Growth was inhibited by +11SSO transfection in a dose-dependent manner.

[0104] Figure 4

[0105] TAF2 pseudoexon inclusion inhibits lung cancer cell growth and proliferation. (A) RT-PCR analysis of TAF2 pseudoexon splicing in NCI-H358 cells transfected with TAF2 pseudoexon +11SSO and non-targeting SSO control. The upper band includes the pseudoexon, which is activated by transfection of +11SSO. (B) Cell proliferation assay showing growth curves (cell confluence relative to time post-transfection) of NCI-H358 cells transfected with TAF2 pseudo exon + 11 SSO and non-targeted SSO controls. Growth was inhibited by +11 SSO transfection. (C) Bar graph from WST-1 cell viability and growth assay showing absorbance at 450 nm as a measure of cell viability of NCI-H358 lung cancer cells transfected with TAF2 pseudo exon + 11 SSO and non-targeted SSO controls. Cell viability was reduced by +11 SSO transfection.

[0106] Figure 5

[0107] Optimization of TRPM7 SSOs targeting the optimal site region. (A+B) RT-PCR analysis of TRPM7 pseudoexon splicing in (A) HeLa cells and (B) U251 cells transfected with 20 nM TRPM7 +9, +10, +11, +12, and +13 SSOs, including controls; untransfected cells transfected with a non-targeting control SSO and treated with or without transfection reagent (UTR). The upper band includes pseudoexons and is increased in number by transfection with +9 to +13 SSOs. (C) Bar graph of cell proliferation assay showing relative cell counts 68 hours after transfection with TRPM7 sham exon +13SSO and TRPM7 siRNA (KD), including control; transfection with non-targeting control SSO and untransfected cells treated with transfection reagent (RNAiMAX) or without transfection reagent (UTR). Growth was inhibited by +13SSO transfection. Student's t test, *p<0.05, **p<0.01 and ***p<0.001.

[0108] Figure 6

[0109] Optimization of HIF1A SSOs for the optimal site region. (A) RT-PCR analysis of HIF1A pseudoexon splicing in U251 cells transfected with HIF1A pseudoexons +9, +10, +11, +12, and +13 SSOs. The middle band includes the pseudoexons, and the efficiency is highest with +10 SSO. Pseudoexon inclusion levels were quantified using a fragment analyzer (Advanced Analytical Technologies). (B) WST-1 assay showing absorbance as a measure of growth and proliferation of U251 cells transfected with 20 nM HIF1A pseudoexon +10 SSO and non-targeting SSO controls under normoxic (N) or hypoxic (H) conditions. Student's t test, *p<0.05, **p<0.01, and ***p<0.001. (C) Western blot of proteins extracted from PANC-1 cells transfected with 20 nM HIF1A pseudo exon +10 SSO, non-targeting SSO control, and untransfected cells (UT) under normoxic or hypoxic conditions using HIF-1α-specific antibodies and β-actin-specific antibodies as loading controls. HIF-1α protein is absent under normoxic conditions but is produced under control hypoxic conditions. +10 SSO reduces HIF-1α protein translation under hypoxic conditions.

[0110] Figure 7

[0111] RNF115 pseudoexon inclusion leads to reduced RNF115 protein levels and inhibits the growth of lung adenocarcinoma cells. (A) RT-PCR analysis of RNF115 pseudoexon splicing in NCI-H23 cells transfected with RNF115 pseudoexon +11SSO and non-targeted SSO control. The upper band includes the pseudoexon, which is activated by transfection with +11SSO. (B) WST-1 assay showing the growth of NCI-H23 cells transfected with different concentrations of RNF115 +11SSO and non-targeted SSO control. Growth was inhibited by +11SSO transfection in a dose-dependent manner. (C) Western blot of proteins extracted from NCI-H23 cells transfected with 5, 10, and 20 nM RNF115 sham exon +11 SSO, non-targeting SSO control, and untransfected cells (UT) using RNF115-specific antibodies, β-catenin antibodies, and β-actin-specific antibodies as loading controls. The protein levels of RNF115 and β-catenin were reduced by +11 SSO.

[0112] Figure 8

[0113] SMAD2 pseudoexon inclusion reduces fibrosis in hepatic stellate cells. (A) RT-PCR analysis of SMAD2 pseudoexon splicing in HeLa cells transfected with SMAD2+11SSO and non-targeting SSO control. The upper band includes the pseudoexon, which is activated by transfection with +11SSO. (B) RT-PCR analysis of SMAD2 pseudoexon splicing in LX-2 hepatic stellate cells transfected with SMAD2+11SSO and non-targeting SSO control. (C) Western blot analysis of proteins from HepG2 hepatocytes transfected with SMAD2 SSO, non-targeting control SSO, or untransfected (UTR) HepG2 cells stimulated with (+) or without (-) TGFβ for 16 hours prior to protein collection. Transfection with +11SSO reduces SMAD2, as well as phosphorylated SMAD2 during TGFβ stimulation. (D) LX-2 hepatic stellate cells were transfected with SMAD2+11SSO or non-targeting SSO control and stimulated with TGFβ for 72 hours. Phase contrast images of cells were captured and the number of differentiated cells was counted in ImageJ. Reduction of SMAD2 with +11SSO reduced the formation of myofibroblasts during TGFβ-stimulated fibrosis.

[0114] Fig. 9

[0115] SSO-mediated inclusion of LRRK2 pseudoexons. (A) Schematic diagram of the results of inducing LRRK2 pseudoexon inclusion. Inclusion of a 54nt pseudoexon from LRRK2 intron 47 will introduce 18 amino acids into the WD40 domain of the translated LRRK2 protein, and inclusion of an 82nt pseudoexon with the same 5' splice site will result in frameshift and insertion of a premature stop codon, which is a target for transcript degradation by nonsense-mediated mRNA decay (NMD). (B) RT-PCR analysis of LRRK2 pseudoexon splicing in HeLa and U251 cells transfected with LRRK2 pseudoexon +11SSO and non-targeting SSO control (ctrl SSO). The upper band includes the pseudoexon, which is activated for inclusion in the mRNA by transfection of +11SSO. UT: untransfected.

[0116] Fig.10

[0117] The potential for SSO-mediated activation of the LRRK2 pseudoexon: chr12:40322690-40322887(+) depends on the presence of a common SNP: rs10878372A / G at the pseudoexon 5' splice site, which enables G allele-specific activation of the pseudoexon. (A) Schematic diagram of SSO treatment targeting the optimal site region of the LRRK2 pseudoexon in the A allele. The pseudoexon 5' splice site (AGAgtagat) (SEQ ID NO:368) has a low MaxEnt score of -4.26. SSO treatment does not induce pseudoexon inclusion from the A allele and produces normal mRNA transcripts that can be translated into functional protein. This was demonstrated by RT-PCR analysis of LRRK2 pseudoexon splicing in A549 cells (homozygous for the A allele) transfected with LRRK2 pseudoexon +11 SSO (5'-CAGACUACCAGACAUCUGACUAGAA-3') (SEQ ID NO: 333) and non-targeting SSO control (ctrl SSO) (5'-GCUCAAUAUGCUACUGCCAUGCUUG-3') (SEQ ID NO: 126), where no bands with pseudoexon inclusion were detected on agarose gel. (B) Schematic representation of SSO treatment targeting the optimal site region of the LRRK2 pseudoexon in the G allele. The pseudoexon 5' splice site (AGAgtaggt) (SEQ ID NO: 369) has a high MaxEnt score of 4.84. SSO treatment induces pseudoexon inclusion from the G allele, and inclusion of pseudoexons will introduce several in-frame premature termination codons (PTCs) that will target mRNA transcripts for degradation by nonsense-mediated mRNA decay (NMD) and / or lead to translation of truncated proteins. This was demonstrated by RT-PCR analysis of LRRK2 pseudoexon splicing in LX-2 cells (heterozygous for the G allele) transfected with LRRK2 pseudoexon +11 SSO (5'-CAGACUACCAGACAUCUGACUAGAA-3') (SEQ ID NO: 333) and non-targeting SSO control (ctrlSSO) (5'-GCUCAAUAUGCUACUGCCAUGCUUG-3') (SEQ ID NO: 126), where the upper band on the agarose gel represents pseudoexon inclusion. When the identified SNP (G) and the dominant pathogenic mutation are located on the same allele, G allele-specific pseudoexon activation allows downregulation of the hyperactivated LRRK2 disease allele with minimal or no effect on the wild-type. Ψ: pseudoexon, WT: wild-type, MUT: mutant.

[0118] Fig.11

[0119] Pseudoexon activation mediated by SSOs targeting the optimal site region (+9 to +39 nt downstream of the 5' splice site) is dependent on the strength of the pseudoexon 3' and 5' splice sites. SNPs located at the 23-mer 3' splice site (-20 to +3 nt of the intron-exon boundary) or the 9-mer 5' splice site (-3 to +6 nt of the exon-intron boundary) affect the strength of a given splice site (alter the MaxEnt score) and can be used for allele-specific pseudoexon activation because such SNPs can render otherwise non-responsive pseudoexons functional targets for SSO treatment, thereby allowing allele-specific inclusion or increased inclusion of a given pseudoexon in mature mRNA. (A) In alleles with low MaxEnt-scoring SNP variants in the pseudoexon 3' or 5' splice site, SSO-mediated pseudoexon activation is not possible or is possible only to a low extent. Normal mRNA transcripts are produced and can be translated into functional proteins. (B) The SNP variant enhances the pseudoexon 3' splice site (increases the MaxEnt score) and allows SSO-mediated pseudoexon activation of alleles with specific 3' splice site high MaxEnt score SNP variants to occur. (C) The SNP variant enhances the pseudoexon 5' splice site (increases the MaxEnt score) and allows SSO-mediated pseudoexon activation of alleles with specific 5' splice site high MaxEnt score SNP variants to occur. In both cases, pseudoexon inclusion can target mRNA transcripts for degradation through nonsense-mediated mRNA decay (NMD) or lead to translation of truncated and non-functional proteins, thereby regulating gene expression. When the identified high MaxEnt score SNP variant and the pathogenic mutation are located on the same allele, the activation of the allele-specific pseudoexon in the heterozygote can allow the downregulation of the disease allele, while having little or no effect on the wild type. For high MaxEnt score SNP variants, the pseudoexon will be activated by both alleles in the homozygote. * indicates the possible position of SNPs that affect the strength of the 3' or 5' splice sites of the pseudoexon. Ψ: pseudoexon, WT: wild type, MUT: mutant.

[0120] The present invention will now be described in more detail hereinafter. DETAILED DESCRIPTION

[0121] definition

[0122] Before discussing the present invention in further detail, the following terms and conventions will first be defined:

[0123] Pseudoexon (PE)

[0124] As used herein, the term "pseudoexon" or "PE" refers to an exon-like sequence that is present within an intronic region but is generally ignored by the spliceosomal system. Thus, under normal splicing conditions, the pseudoexon does not become part of the mature mRNA, or only becomes part of the mature mRNA at a low level. Thus, a pseudoexon is an intronic sequence flanked by 3' and 5' splice sites, but since it is generally rarely included in the mRNA transcript, the pseudoexon is usually not annotated. Furthermore, when included, the pseudoexon will disrupt or significantly alter the function of the normal transcript or protein.

[0125] Functionally disabling pseudoexons

[0126] In the present context, the term "functionally disabling pseudoexon" relates to a situation where the presence of a pseudoexon in a mature mRNA results in inactivation, reduced activity, decreased transcription and / or altered function of the protein expressed by the mRNA (compared to a mature mRNA without the pseudoexon).

[0127] Exonic splicing enhancer (ESE)

[0128] As used herein, the term "exonic splicing enhancer" or "exonic splicing enhancer" or "ESE" refers to a nucleotide sequence that, when present in an exon and made available due to binding of nuclear splicing regulatory proteins and / or by forming a secondary structure of the pre-mRNA or a portion thereof, stimulates the inclusion of the exon into the final spliced ​​mRNA during the pre-mRNA splicing process.

[0129] Exonic splicing silencer (ESS)

[0130] As used herein, the term "exonic splicing silencer" or "exonic splicing silencer" or "ESS" refers to a nucleotide sequence that, when present in an exon and made available due to binding of a nuclear splicing regulatory protein and / or by forming a secondary structure of the pre-mRNA or a portion thereof, inhibits the inclusion of the exon into the final spliced ​​mRNA during the pre-mRNA splicing process.

[0131] Intronic splicing enhancer (ISE)

[0132] As used herein, the term "intronic splicing enhancer" or "intronic splicing enhancer" or "ISE" refers to a nucleotide sequence that, when present in an intron and made available due to binding of nuclear splicing regulatory proteins and / or by forming a secondary structure of the pre-mRNA or a portion thereof, stimulates the inclusion of the intron into the final spliced ​​mRNA during the pre-mRNA splicing process.

[0133] Intronic splicing silencer (ISS)

[0134] As used herein, the term "intronic splicing silencer" or "intronic splicing silencer" or "ISS" refers to a nucleotide sequence that, when present in an intron and made available due to binding of nuclear splicing regulatory proteins and / or by forming a secondary structure of the pre-mRNA or a portion thereof, inhibits the inclusion of the intron into the final spliced ​​mRNA during the pre-mRNA splicing process.

[0135] Splice site

[0136] The splice site at the 5' end of an intron is often referred to as the "5' splice site" or "splice donor site", and the splice site at the 3' end of an intron is often referred to as the "3' splice site" or "splice acceptor site".

[0137] Nonsense-mediated mRNA decay (NMD)

[0138] "Nonsense-mediated mRNA decay" or "NMD" is a surveillance pathway present in all eukaryotic organisms. Its main function is to reduce errors in gene expression by eliminating mRNA transcripts containing premature termination codons (PTCs). With respect to the present invention, the introduction of pseudoexons can induce NMD if the PTC is present in the introduced pseudoexon or when the pseudoexon changes the reading frame of the mature transcript.

[0139] Nucleotides

[0140] As used herein, "nucleotide" refers to a nucleoside further comprising a phosphate linking group. As used herein, "connected nucleosides" may be connected by or without a phosphate bond, and therefore include but are not limited to "connected nucleotides". As used herein, "connected nucleosides" are nucleosides connected in a continuous sequence (i.e., there are no additional nucleosides between the connected nucleosides).

[0141] Nucleobase

[0142] As used herein, "nucleobase" refers to a group of atoms that can be linked to a sugar moiety to produce a nucleoside that can be incorporated into an oligonucleotide, and wherein the group of atoms is capable of binding to a complementary naturally occurring nucleobase of another oligonucleotide or nucleic acid. Nucleobases can be naturally occurring or modified.

[0143] Unmodified nucleobases

[0144] As used herein, the term "unmodified nucleobase" or "naturally occurring nucleobase" refers to the naturally occurring heterocyclic nucleobases of RNA or DNA: the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) (including 5-methyl C), and uracil (U).

[0145] Modified Nucleobases

[0146] As used herein, "modified nucleobase" refers to any nucleobase that is not a naturally occurring nucleobase.

[0147] Modified Nucleosides

[0148] As used herein, "modified nucleosides" refer to nucleosides that contain at least one chemical modification compared to naturally occurring RNA or DNA nucleosides. Modified nucleosides contain modified sugar moieties and / or modified nucleobases.

[0149] Constrained ethyl nucleoside (cEt)

[0150] As used herein, "constrained ethyl nucleoside" or "cEt" refers to a nucleoside comprising a bicyclic sugar moiety comprising a 4'-CH(CH3)-0-2' bridge.

[0151] Locked Nucleoside (LNA)

[0152] As used herein, "locked nucleic acid nucleoside" or "LNA" refers to a nucleoside comprising a bicyclic sugar moiety comprising a 4'-CH2-0-2' bridge.

[0153] 2'-Substituted Nucleosides

[0154] As used herein, "2'-substituted nucleoside" refers to a nucleoside that contains a substituent other than H or OH at the 2'-position. Unless otherwise indicated, a 2'-substituted nucleoside is not a bicyclic nucleoside.

[0155] 2'-Deoxynucleoside

[0156] As used herein, "2'-deoxynucleoside" refers to a nucleoside comprising a 2'-H furanosyl sugar moiety, as found in naturally occurring deoxyribonucleosides (DNA). In certain embodiments, a 2'-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (eg, uracil).

[0157] Oligonucleotides

[0158] As used herein, "oligonucleotide" refers to a compound comprising a plurality of linked nucleosides. In certain embodiments, an oligonucleotide comprises one or more unmodified ribonucleosides (RNA) and / or unmodified deoxyribonucleosides (DNA) and / or one or more modified nucleosides.

[0159] Terminal Group

[0160] As used herein, "terminal group" refers to one or more atoms attached to either or both of the 3' end or the 5' end of an oligonucleotide. In certain embodiments, the terminal group is a conjugate group. In certain embodiments, the terminal group comprises one or more terminal group nucleosides.

[0161] Conjugate

[0162] As used herein, "conjugate" refers to an atom or group of atoms that is bound to an oligonucleotide or oligomeric compound. Typically, conjugate groups modify one or more properties of the compound to which they are attached, including but not limited to pharmacodynamics, pharmacokinetics, binding, absorption, cellular distribution, cellular uptake, charge and / or clearance properties.

[0163] Conjugate Linking Group

[0164] As used herein, "conjugate linking group" refers to any atom or group of atoms used to link a conjugate to an oligonucleotide or oligomeric compound.

[0165] Splice Switching Oligonucleotides (SSO)

[0166] As used herein, "splice switching oligonucleotide" or "SSO" refers to a compound comprising or consisting of an oligonucleotide, at least a portion of which is complementary to a target nucleic acid to which it is capable of hybridizing, resulting in at least one alteration in the splicing pattern of a targeted pre-mRNA.

[0167] Splice-switching oligonucleotides may also be referred to as splice-switching antisense oligomers (SSOs).

[0168] mRNA

[0169] As used herein, "mRNA" refers to an RNA molecule that encodes a protein.

[0170] Pre-mRNA

[0171] As used herein, "pre-mRNA" refers to an RNA transcript that has not yet been fully processed into mRNA. The pre-mRNA includes one or more introns.

[0172] Target pre-mRNA

[0173] As used herein, the term "target pre-mRNA" refers to a nucleic acid molecule to which a SSO hybridizes.

[0174] Targeting changes in pre-mRNA splicing patterns

[0175] As used herein, "alteration of the splicing pattern of a targeted pre-mRNA" refers to an alteration in the splicing process of a pre-mRNA that results in the insertion of a portion (e.g., corresponding to a pseudoexon or a portion thereof) into the resulting mRNA when compared to a reference nucleotide sequence of the targeted pre-mRNA.

[0176] Transcript

[0177] As used herein, "transcript" refers to an RNA molecule transcribed from DNA. Transcripts include, but are not limited to, mRNA, pre-mRNA, and partially processed RNA.

[0178] Targeting and Targeting to

[0179] As used herein, "targeting" or "targeting to" refers to the binding of an SSO to a specific target nucleic acid molecule or a specific region of a target nucleic acid molecule. An SSO targets a target nucleic acid if the SSO is sufficiently complementary to the target nucleic acid to allow hybridization under physiological conditions.

[0180] Nucleobase complementarity and complementarity

[0181] As used herein, "nucleobase complementarity" or "complementarity" refers to a nucleobase that can base pair with another nucleobase when it comes to a nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, a complementary nucleobase refers to a nucleobase in an SSO that can base pair with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an SSO can hydrogen bond with a nucleobase at a certain position of a target nucleic acid, then the hydrogen bonding position between the oligonucleotide and the target nucleic acid is considered to be complementary on the nucleobase pair. Nucleobases containing certain modifications can maintain the ability to pair with corresponding nucleobases and are therefore still capable of nucleobase complementarity.

[0182] As used herein, "complementarity" related to an oligomeric compound (e.g., a connected nucleoside, oligonucleotide or nucleic acid) refers to the ability of such an oligomeric compound or its region to hybridize with another oligomeric compound or its region under stringent conditions by core base complementarity. Complementary oligomeric compounds do not need to have core base complementarity on each nucleoside. On the contrary, some mispairings are acceptable. In certain embodiments, complementary oligomeric compounds or regions are complementary (70% complementary) at 70% of the core bases. In certain embodiments, complementary oligomeric compounds or regions are 80% complementary. In certain embodiments, complementary oligomeric compounds or regions are 90% complementary. In certain embodiments, complementary oligomeric compounds or regions are 95% complementary. In certain embodiments, complementary oligomeric compounds or regions are 100% complementary. In another embodiment, the oligomeric compound comprises up to 3 mispairings, such as up to 2 or 1 mispairings. Preferably, there is no mispairing.

[0183] Hybridization

[0184] As used herein, "hybridization" refers to the pairing of complementary oligomeric compounds (e.g., an SSO and its target nucleic acid). Although not limited to a particular mechanism, the most common mechanism of pairing involves hydrogen bonding between complementary nucleobases, which can be Watson-Crick, Hoogsteen, or reversed Hoogsteen hydrogen bonding.

[0185] Motif

[0186] As used herein, "motif" refers to a pattern of chemical modifications in an oligomeric compound or a region thereof. A motif can be defined by modifications on certain nucleosides and / or certain linker groups of an oligomeric compound.

[0187] As used herein, "nucleoside motif" refers to a nucleoside modification pattern in an oligomeric compound or region thereof. The connection of such an oligomeric compound may be modified or unmodified. Unless otherwise indicated, herein only a motif describing a nucleoside refers to a nucleoside motif. Therefore, in this case, the connection is not limited.

[0188] As used herein, "sugar motif" refers to a pattern of sugar modifications in an oligomeric compound or a region thereof.

[0189] As used herein, "linking motif" refers to a connection modification pattern in an oligomeric compound or region thereof. The nucleosides of such oligomeric compounds may be modified or unmodified. Unless otherwise indicated, motifs describing only connection herein refer to connection motifs. Therefore, in this case, nucleosides are not limited.

[0190] Modification Type

[0191] As used herein, the "modification type" of a nucleoside or a certain "type" of nucleosides refers to the chemical modification of the nucleoside, including modified and unmodified nucleosides. Therefore, unless otherwise specified, a "nucleoside with a first type of modification" can be an unmodified nucleoside.

[0192] Differently modified

[0193] As used herein, "differently modified" refers to chemical modifications or chemical substituents that are different from each other, including no modification. Thus, for example, MOE nucleosides and unmodified DNA nucleosides are "differently modified", although the DNA nucleosides are unmodified. Similarly, DNA and RNA are "differently modified", although both are naturally occurring unmodified nucleosides. Identical nucleosides that contain different nucleobases are not differently modified. For example, a nucleoside containing a 2'-OMe modified sugar and an unmodified adenine nucleobase and a nucleoside containing a 2'-OMe modified sugar and an unmodified thymine nucleobase are not differently modified.

[0194] MaxEnt Rating

[0195] The MaxEnt score is a score known to the skilled person that takes into account adjacent and non-adjacent dependencies between positions within a splice site, using the maximum entropy principle to determine the best splice site. A high score indicates a high probability of a functional splice site, but a low-scoring splice site may function through activation of splicing factors that bind to pre-mRNAs with ESE or ISE motifs. Similarly, a high-scoring splice site may be functionally inhibited by an inhibitory splicing factor that binds to a nearby or overlapping ESS or ISS motif.

[0196] The MaxEnt score according to the invention is determined using the program "MaxEntScan" version 20-04-2004. The same software can be used to determine:

[0197] 5' splice site scoring:

[0198] (http: / / hollywood.mit.edu / burgelab / maxent / Xmaxentscan_scoreseq.html); and

[0199] 3' splice site scoring:

[0200] (http: / / hollywood.mit.edu / burgelab / maxent / Xmaxentscan_scoreseq_acc.html

[0201] ).

[0202] The determination of the MaxEnt score is further described by Gene Yeo and Christopher B Burge (J Comput Biol. 2004; 11(2-3):377-94).

[0203] The MaxEnt score is a specific value that can only be determined in one way.

[0204] Although inclusion of the MaxEnt score significantly improves overall predictability and is preferred, in certain embodiments of the invention, the MaxEnt score is optional.

[0205] False exon identification

[0206] Pseudo-exons are identified using a double-join approach with precise genomic coordinates of the 3' splice site and the 5' splice site. In this approach, RNA sequencing fragments are filtered to retain only those with evidence of at least two splice junctions. Exon coordinates can be extracted from the mapped reads, allowing for gaps of a certain length in the middle of fragments with no direct sequence. Exons supported by splice junctions at both ends of the same fragment are classified by comparison with known gene annotations, and novel pseudo-exons can be identified as exons that overlap with introns, but not any existing exons.

[0207] The "sweet spot region" is defined as the region from +9 to +39, inclusive, downstream of the 5' splice site of the pseudo-exon. Pseudo-exons that can be activated by SSOs that bind to regions within the sweet spot region are identified by the following parameters:

[0208] False exon parameters / criteria:

[0209] Pseudoexon length <160 nt;

[0210] Pseudoexon length > 30 nt;

[0211] The last 3 nt of the pseudoexon is different from TAG;

[0212] MaxEnt score of the donor splice site ≥ 4.33;

[0213] MaxEnt score of the donor splice site ≤ 10.06; and

[0214] The MaxEnt score of the receptor splice site is ≥3.63;

[0215] Parameters / criteria for the +9 to +39 sequence region downstream of the 5' splice site of the pseudoexon:

[0216] ●Total pyrimidines ≤ 20;

[0217] Total thymidine bases ≤ 12;

[0218] ●Total thymidine bases ≥4;

[0219] Total guanine bases ≤ 12;

[0220] The maximum length of thymidine polymer is ≤ 4;

[0221] The maximum length of pyrimidine polymer is ≤10;

[0222] The minimum length of purine polymer is ≥ 3; and

[0223] ●The maximum number of guanine polymers with a length of at least 3 nt is ≤ 2.

[0224] In an RNA sequence, the presence of uracil can be considered equivalent to the presence of thymidine at the same position in the corresponding DNA sequence. Therefore, the presence of thymidine in a DNA sequence can also be considered equivalent to uracil at the same position in the corresponding RNA sequence. Therefore, when the sequence analyzed is an RNA sequence, the criteria for covering sequences with thymidine and pyrimidine are the same as the equivalent criteria for sequences with uracil and pyrimidine.

[0225] Identify sequences and prepare SSOs

[0226] As described above, the present invention relates to identifying sequence parameters in a gene comprising a pseudoexon, which can be used to determine whether it is possible (highly likely) that the pseudoexon will be incorporated into a mature mRNA using a splice switching oligonucleotide (SSO) (see also Example 1 and the corresponding figures). Therefore, one aspect of the present invention relates to a method for identifying an SSO that is capable of regulating the expression of a target protein in a cell by promoting the incorporation of the pseudoexon into a mature mRNA when binding to a pre-mRNA in the region +9 to +39 downstream of the 5' splice site of the pseudoexon, the method comprising:

[0227] a) providing one or more gene sequences comprising one or more identified pseudoexons;

[0228] b) determining one or more gene sequences; if the pseudoexon meets the following criteria:

[0229] Pseudoexon length <160 nt;

[0230] Pseudoexon length > 30 nt;

[0231] The last 3 nt of the pseudoexon is different from TAG;

[0232] MaxEnt score of the donor splice site ≥ 4.33;

[0233] MaxEnt score of the donor splice site ≤ 10.06; and

[0234] The MaxEnt score of the receptor splice site is ≥3.63;

[0235] c) determining the position of the pseudo exon (3) downstream of the 5' splice site from +9 to

[0236] Does the +39 sequence region meet the following criteria:

[0237] Total pyrimidines ≤ 20;

[0238] Total thymidine bases ≤ 12;

[0239] Total thymidine bases>=4;

[0240] Total guanine bases ≤ 12;

[0241] ●The maximum length of thymidine polymer is ≤ 4;

[0242] The maximum length of pyrimidine polymer is ≤10;

[0243] The maximum length of purine polymer is ≥3; and

[0244] The maximum number of guanine polymers of at least 3 nt in length is ≤ 2.

[0245] Wherein, if one or more gene sequences meet the criteria according to item b) and item c), the +9 to +39 region downstream of the 5' splice site of the pseudo exon is considered to be a target of the SSO, which is capable of hybridizing in vivo with the pre-mRNA (2) of the gene in the +9 to +39 region downstream of the 5' splice site of the pseudo exon (3); and causing the pseudo exon (3) to become part of the mature mRNA to a greater extent compared to the corresponding pre-mRNA not contacted with the SSO (1);

[0246] as well as

[0247] Optionally, the SSO is prepared, optionally for use as a medicament.

[0248] As outlined in Example 2, the included selection parameters (criteria) can distinguish between genes where SSOs can be used (Table 1 in Example 2) and genes where SSOs will not be able to incorporate pseudoexons (Table 2 in Example 2).

[0249] In one embodiment, the invention is computer implemented (except for the optional step of preparing said SSO for optional use as a medicament).

[0250] In another embodiment, one or more gene sequences comprising one or more identified pseudoexons are provided in the form of a database or another digital storage means.

[0251] In one embodiment, the one or more gene sequences comprising one or more identified pseudoexons are gene sequences comprising a disease-causing gene, such as a gene encoding a dominant negative protein, such as characterized by increased expression or altered function of the gene.

[0252] In another embodiment, the pseudoexon is located in a gene in which reduced levels of a normal functional gene product are of therapeutic benefit, such as genes associated with cancer, diabetes, inflammation, neurodegenerative or neurological disorders, tissue degeneration, tissue fibrosis and chirosis, metabolic conditions, chronic liver disease, and inherited retinal dystrophy (IRD).

[0253] In another embodiment, the one or more gene sequences comprising one or more identified pseudoexons are gene sequences containing pathogenic genes, such as genes encoding proteins that cause / enhance / affect diseases such as cancer, diabetes, inflammation, neurodegenerative or neurological disorders, tissue degeneration, tissue fibrosis and chirosis, metabolic conditions, chronic liver disease, and inherited retinal dystrophy (IRD). The disease may be due to enhanced expression.

[0254] In another embodiment, the one or more gene sequences comprising the one or more identified pseudoexons are gene sequences that are not only known to cause a genetic disease.

[0255] In a preferred embodiment, SSOs are prepared for the identified region +9 to +39 downstream of the 5' splice site of the pseudoexon, which region meets the above criteria. Examples 3-10 show specific examples of the effects of SSOs on identified target sequences.

[0256] In one embodiment, the prepared SSO comprises a sequence complementary or substantially complementary to the +9 to +39 region downstream of the 5' splice site of the pseudo exon (3), such as within the +11 to +35 region downstream of the 5' splice site. In the Examples section (Examples 2-8), an SSO (25 nt long) complementary to the +11 to +35 position was used. In Examples 9 and 10, the specific optimization of the target region of the SSO has been further optimized for two genes, HIF1A and TRPM7. In Examples 3 and 13, the specific optimization of the target region of the SSO has been further optimized for two genes, SMAD2 and LRRK2.

[0257] In another embodiment, the prepared SSO comprises a sequence that is substantially complementary to the region from +9 to +39 downstream of the 5' splice site of the pseudoexon (3) and comprises at most 3 mismatches, such as at most 2 mismatches or such as at most 1 mismatch.

[0258] In one embodiment, the prepared SSO comprises a sequence complementary to the region +9 to +39 downstream of the 5' splice site of the pseudo exon (3), such as within the region +11 to +35 downstream of the 5' splice site. In this example, an SSO targeting the +11 to +35 position was tested.

[0259] In one embodiment, the complementary region is in the range of 9-31 nucleotides, such as 15-30, such as 15-25 or such as 9-15, or such as 15-30, such as 20-25. The length of the SSO may be in the shorter range if, for example, LNA or other high binding nucleotides are used.

[0260] SSOs may be able to regulate the expression of target proteins in different ways. Thus, in one embodiment, hybridization of SSOs with pre-mRNA in vivo results in:

[0261] - reduced levels of mRNA encoding a functional protein (4); and / or

[0262] - reduced expression of functional protein (6); and / or

[0263] - loss of function of the functional protein (5); and / or

[0264] - a new function of the functional protein (6); and / or

[0265] - Mislocalization of proteins.

[0266] - Mislocalization of mRNA encoding a functional protein.

[0267] In another embodiment, the one or more gene sequences from step a) cause a disorder or condition characterized by increased gene expression or altered function. In one embodiment, the disorder or condition is an autosomal dominant negative disorder.

[0268] In another embodiment, the one or more gene sequences from step a) are therapeutically beneficial when the level of a normally functional gene product is reduced. In one embodiment, the disorder or condition is not directly associated with a disease-causing gene.

[0269] In one embodiment, the length of the SSO is in the range of 9-100 nucleotides, such as 9-50 nucleotides, preferably in the range of 9-40 nucleotides, more preferably in the range of 15-31 nucleotides or 15-25 nucleotides.

[0270] In one embodiment, the SSO comprises a sequence that is complementary or substantially complementary to a polynucleotide in a pre-mRNA, wherein the length of the sequence is in the range of 9-31 nucleotides, such as 15-25 nucleotides, preferably the sequence is complementary in the range of 9-31 nucleotides, such as 9-20, or such as 20-31 nucleotides, such as 25-31 nucleotides.

[0271] In a preferred embodiment, the prepared SSO comprises one or more artificial nucleotides, such as sugar-modified nucleotides.

[0272] In another preferred embodiment, the SSO does not mediate RNase H-mediated mRNA degradation in vivo.

[0273] In one embodiment, at least one modified sugar moiety is a 2'-substituted sugar moiety.

[0274] In one embodiment, the 2'-substituted sugar moiety has a 2'-substitution selected from the group consisting of 2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), and 2'-O-methoxyethyl (2'-MOE).

[0275] In one embodiment, the 2'-substitution of the at least one 2'-substituted sugar moiety is 2'-O-methoxyethyl (2'-MOE).

[0276] In one embodiment, at least one modified sugar moiety is a bicyclic sugar moiety.

[0277] In one embodiment, at least one bicyclic sugar moiety is a locked nucleic acid (LNA) or a constrained ethyl (cEt) nucleoside.

[0278] In one embodiment, at least one sugar moiety is a sugar substitute.

[0279] In one embodiment, at least one sugar substitute is a morpholino.

[0280] In one embodiment, at least one morpholino is a modified morpholino.

[0281] In one embodiment, the SSO comprises at least one internucleoside N3' to P5' phosphorothioate linkage.

[0282] In one embodiment, the modified oligonucleotide comprises at least one internucleoside phosphorothioate linkage.

[0283] In one embodiment, all internucleoside linkages are phosphorothioate.

[0284] In one embodiment, the SSO is conjugated to a delivery element, such as selected from the group consisting of Gal-Nac, (poly)unsaturated fatty acids (such as oleoyl and linolenoyl), anisamide, anandamide, folic acid (FolA), carbachol, estrone, Retro-1, phospholipids, α-tocopherol (α-TP), cholesterol, squalene (SQ), unbranched fatty acids (such as lauroyl, myristoyl, palmitoyl, stearoyl and behenoyl) and cell penetrating peptides.

[0285] In one embodiment, the one or more gene sequences comprising one or more identified pseudoexons are involved in a disease or disorder selected from the group consisting of cancer, inflammatory diseases, neurodegenerative or neurological diseases, metabolic conditions, chronic liver diseases, and inherited retinal dystrophy (IRD).

[0286] In one embodiment, the chronic liver disease is non-alcoholic fatty liver disease.

[0287] In one embodiment, the cancer is selected from the group consisting of brain cancer, glioblastoma, lung cancer, colorectal cancer, skin cancer, pancreatic cancer, bladder cancer, liver cancer, breast cancer, eye cancer, and prostate cancer.

[0288] In another embodiment, the cancer is a hematological cancer, such as selected from the group consisting of multiple myeloma, acute myeloblastic leukemia, chronic myeloblastic leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia.

[0289] As described in the Examples section, the present team has identified a number of clinically relevant genes containing pseudoexons that can be incorporated into mature mRNAs, thereby inactivating / inhibiting / altering the function of the expressed (disease-causing) proteins.

[0290] Thus, in one embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0291] - a nucleic acid according to any one of SEQ ID NOs: 106 (RNF115), 1-26, 79-105, 107-125 and 137-201; or

[0292] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0293] - A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201.

[0294] In a preferred embodiment, the prepared SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0295] - a nucleic acid according to any one of SEQ ID NOs: 79-100; or

[0296] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 79-100;

[0297] or

[0298] - a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 79-100.

[0299] In a more preferred embodiment, the prepared SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0300] - a nucleic acid according to any one of SEQ ID NOs: 79-85; or

[0301] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 79-85;

[0302] or

[0303] - a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 79-85.

[0304] Based on the gene sequence data provided in the Examples section, a skilled person can easily translate this information into a specific SSO sequence, for example by using the underlined parts in the table and designing an SSO complementary thereto.

[0305] In one embodiment, the SSO is selected from the group consisting of:

[0306] - a nucleic acid according to any one of SEQ ID NOs: 127-136; or

[0307] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 127-136;

[0308] or

[0309] - a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 127-136.

[0310] Preferably, the nucleic acid is SEQ ID NO: 127 or 128 or 133 or 136. As shown in Examples 9 and 10, these SSOs have been optimized in the region of the best site. Therefore, by moving the binding region, for example only 1 or 2 positions, the efficiency can surprisingly be further increased. More preferably, the nucleic acid is SEQ ID NO: 128 or 136.

[0311] In another preferred embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0312] o According to SEQ ID NO: 21 (targeting SMAD2), SEQ ID NO: 106 (targeting RNF115)

[0313] Any one of and SEQ ID NO: 141, 142, 158 and 159 (targeting LRRK2)

[0314] Any nucleic acid of

[0315] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 21, 106, 141, 142, 158 and 159; or

[0316] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 21, 106, 141, 142, 158 and 159.

[0317] Example 3 shows data on SMAD2 targeting (see also Example 11).

[0318] Example 12 shows data on RNF115 targeting.

[0319] Example 13 shows data on LRRK2 targeting, including allele-specific targeting.

[0320] In another preferred embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0321] o a nucleic acid according to any one of SEQ ID NOs: 100, 114, 118, 150 and 151;

[0322] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 100, 114, 118, 150 and 151; or

[0323] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 100, 114, 118, 150 and 151.

[0324] In another preferred embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0325] o a nucleic acid according to any one of SEQ ID NO: 12, 24 or 26;

[0326] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NO: 12, 24 or 26; or

[0327] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NO: 12, 24 or 26.

[0328] As described in the Examples section, various genes have been targeted using the selection criteria according to the present invention (Example 2, Table 1), or have been identified as targeting sequences using the selection criteria according to the present invention (Example 8, Table 3, Example 11, Tables 6-7). Thus, in one embodiment, the SSOs prepared are complementary or substantially complementary to the SEQ ID NOs summarized in Table 1, Table 3, Table 6 and Table 7 (optimal site regions).

[0329] As described below, the genes listed in Table 1 or Table 3 or Table 6-7 may be particularly preferred when involved in certain diseases. Similarly, Table 1, Table 3 and Table 6-7 list the best sites for SSO. Table 2 shows pseudo exon sequences that do not meet the criteria according to the present invention and are not SSO functional sites.

[0330] Non-matrix cancer (NMD):

[0331] The following genes may be associated with targets for cancer therapy: TXNRD1, SLC7A11, STAT5B, MAPKAPK5, ZYG11A, ROCK1, MCCC2, SMYD2, DIAPH3, COPS3, SNX5, YBX1, CHD1L, PTPN11, UBAP2L, RNF115, HGS, TLK1, WWTR1, HMGCS1, SND1, THOC2, ORC1, TAF2, HIF1A, TRPM7, CPPS1, LRP6, MELK, TTBK2, TTK, ITGBL1, ROCK2, TASP1, FLT1, KNTC1, SMC1A, ZNF558, PMPCB, and DBI.

[0332] Therefore, in one embodiment, the prepared SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and Tables 6-7, wherein the gene is selected from the group consisting of: TXNRD1, SLC7A11, STAT5B, MAPKAPK5, ZYG11A, ROCK1, MCCC2, SMYD2, DIAPH3, COPS3, SNX5, YBX1, CHD1L, PTPN11, UBAP2L, RNF115, HGS, TLK1, WWTR1, HMGCS1, SND1, THOC2, ORC1, TAF2, HIF1A, TRPM7, CPPS1, LRP6, MELK, TTBK2, TTK, ITGBL1, ROCK2, TASP1, FLT1, KNTC1, SMC1A, ZNF558, PMPCB and DBI; for treating cancer. In a preferred embodiment, the gene is RNF115 (see Example 12).

[0333] Cancer within the framework:

[0334] The following genes may be associated with targets for cancer therapy: ROCK1, E2F3, LRIG2, HSPG2, SLC2A1, KNTC1, DIAPH3, FDFT1, THOC2 and SMC1A, DDR2, STAG2, TRPM7, LINGO2, RAP1GDS, BUD1, CD44, CDKL5, RNF115, UBAP2L, ZNF558, RBPJ, EFEMP1, and FLT1.

[0335] Therefore, in one embodiment, the prepared SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and Tables 6-7, wherein the gene is selected from the group consisting of ROCK1, E2F3, LRIG2, HSPG2, SLC2A1, KNTC1, DIAPH3, FDFT1, THOC2, DDR2, STAG2, TRPM7, LINGO2, SMC1A, RAP1GDS, BUD1, CD44, CDKL5, RNF115, UBAP2L, ZNF558, RBPJ, EFEMP1 and FLT1; for treating cancer.

[0336] Neurological diseases (outside the framework):

[0337] The following genes may be associated with targets for neurological diseases: ROCK1, HTT, OGA, TMEM97, PICALM, LRRK2, UBAP2L, SMC1A, TTBK2.

[0338] Therefore, in one embodiment, the prepared SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and Tables 6-7, wherein the gene is selected from the group consisting of: ROCK1, HTT, OGA, TMEM97, PICALM, LRRK2, UBAP2L, SMC1A and TTBK2; for treating neurological diseases. In a preferred embodiment, the gene is LRRK2 (see Example 13).

[0339] In an even more preferred embodiment, the neurological disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Frederick's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease and spinal muscular atrophy.

[0340] Neurodegenerative diseases are progressive loss of neuronal structure or function, including neuronal death. Many neurodegenerative diseases—including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, and prion diseases—occur as a result of a neurodegenerative process.

[0341] Neurological diseases (within the framework):

[0342] The following genes may be associated with targets for neurological diseases: ROCK1, E2F3, SLC2A13, ASIC1, TRPM7, LINGO2, LRIG2, LRRK2, UBAP2L, SMC1A, ATXN7, and CLCN1.

[0343] Therefore, in one embodiment, the prepared SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and Tables 6-7, wherein the gene is selected from the group consisting of: ROCK1, E2F3, SLC2A13, TRPM7, LINGO2, ASIC1, LRIG2, LRRK2, UBAP2L, SMC1A, ATXN7 and CLCN1; for treating neurological diseases.

[0344] Likewise, in an even more preferred embodiment, the neurological disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Frederick's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease and spinal muscular atrophy.

[0345] diabetes:

[0346] The following genes may be associated with diabetes targets: TXNRD1 (diabetes), DYRK1A (diabetes), TRPM7 (diabetes), and PHLPP1 (diabetes and obesity).

[0347] Therefore, in one embodiment, the prepared SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and Tables 6-7, wherein the gene is selected from the group consisting of: TXNRD1, DYRK1A, TRPM7 and PHLPP1; for treating diabetes. In a preferred embodiment, diabetes is selected from type 1 diabetes and type 2 diabetes.

[0348] In another embodiment, the prepared SSO is complementary or substantially complementary to the SEQ ID NOs listed in Table 1, Table 3, and Tables 6-7, wherein the gene is selected from the group consisting of LINGO2, SMAD2, ORC1, DDR2, STAG2, TRPM7, HIF1A, HTT, TAF2, CSPP1, RN115, LRRK2, UBAB2L, LRP6, MELK, and KNTC1. These 16 genes all contain pseudoexons that meet all criteria, are activated by SSOs located in the optimal site region (see Tables 1 and 3, and Tables 6-7), and have high therapeutic potential.

[0349] In one embodiment, the method is computer-implemented. Therefore, the present invention can be implemented by hardware, software, firmware or any combination of these. The present invention or some of its features can also be implemented as software running on one or more data processors and / or digital signal processors.

[0350] The various elements of the embodiments of the present invention can be implemented physically, functionally and logically in any suitable manner, such as in a single unit, in multiple units or as a part of a separate functional unit. The present invention can be implemented in a single unit, or physically and functionally distributed between different units and processors.

[0351] As mentioned above, an SSO can include one or more mismatches. The advantage of introducing such mismatches is that allele-specific targeting is possible. This may be relevant when you only want to target one allele of a gene.

[0352] Tables 4, 5 and 8 list specific SSOs that target genes (pre-mRNA) of the listed genes. Therefore, in one embodiment, the SSO is selected from the SSOs listed in Tables 4, 5 and 8.

[0353] Composition used

[0354] The SSO identified by the method of the present invention can be used as a drug for treating various diseases. Therefore, another aspect of the present invention relates to a composition comprising a splice switching oligonucleotide (SSO) which is complementary or substantially complementary to a target pre-mRNA (e.g., encoding a functional protein that causes a disease or affects a disease), wherein the target pre-mRNA (2) comprises:

[0355] - Functionally disabling pseudoexons, including:

[0356] o 3' splice site at the 5' end; and

[0357] o 5' splice site at the 3' end;

[0358] wherein the SSO is complementary or substantially complementary to the target pre-mRNA in the region +9 to +39 downstream of the 5' splice site of the pseudoexon;

[0359] wherein when the SSO hybridizes in vivo with a pre-mRNA in the region +9 to +39 downstream of the 5' splice site of the pseudo-exon; the pseudo-exon becomes part of the mature mRNA to a greater extent than the corresponding pre-mRNA not contacted with the SSO;

[0360] Used as medicine.

[0361] Thus, SSOs regulate the expression of target proteins by promoting the incorporation of pseudoexons into mature mRNAs.

[0362] SSO-induced regulation can affect the target protein in different ways. Thus, in one embodiment, hybridization of the SSO with the pre-mRNA results in:

[0363] - reduced levels of mRNA encoding functional protein; and / or

[0364] - reduced expression of functional protein; and / or

[0365] - loss of function of a functional protein; and / or

[0366] - New functions of functional proteins; and / or

[0367] - protein mislocalization; and / or

[0368] - Mislocalization of mRNA encoding a functional protein.

[0369] In one embodiment, the composition is used to treat a human subject suffering from a disease or condition characterized by increased expression or altered function of a functional protein that causes or affects the condition, or in which decreased expression of a functional gene product is therapeutically beneficial.

[0370] In one embodiment, the SSO comprises a sequence that is complementary or substantially complementary to a polynucleotide in a pre-mRNA, characterized by the parameters according to the present invention.

[0371] In one embodiment, said SSO comprising a sequence that is substantially complementary to a polynucleotide in a pre-mRNA comprises at most 3 mismatches, such as at most 2 mismatches or such as at most 1 mismatch.

[0372] In one embodiment, the SSO comprises a sequence that is complementary to a polynucleotide in a pre-mRNA according to defined criteria.

[0373] In one embodiment, the region from +9 to +39 relative to the 5' splice site of the pseudoexon comprises a splice regulatory site.

[0374] In another embodiment, the splicing regulatory site is an intronic splicing silencer (ISS) site.

[0375] In one embodiment, the length of the SSO is in the range of 9-100 nucleotides, such as 9-50 nucleotides, preferably in the range of 9-40 nucleotides, more preferably in the range of 9-31 nucleotides or 9-25 nucleotides.

[0376] In one embodiment, the SSO comprises a sequence that is complementary or substantially complementary to a polynucleotide in a pre-mRNA as defined above, wherein the length of the sequence is in the range of 9-31 nucleotides, such as 9-20 nucleotides, preferably the sequence is complementary in the range of 9-31 nucleotides, such as 9-20, or such as 20-31 nucleotides, such as 25-31 nucleotides.

[0377] In one embodiment, the SSO comprises one or more artificial nucleotides, such as sugar-modified nucleotides.

[0378] In one embodiment, the oligonucleotide does not mediate RNase H-mediated mRNA degradation.

[0379] In one embodiment, at least one modified sugar moiety is a 2'-substituted sugar moiety.

[0380] In one embodiment, the 2'-substituted sugar moiety has a 2'-substitution selected from the group consisting of 2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), and 2'-O-methoxyethyl (2'-MOE).

[0381] In one embodiment, the 2'-substitution of the at least one 2'-substituted sugar moiety is 2'-O-methoxyethyl (2'-MOE).

[0382] In one embodiment, at least one modified sugar moiety is a bicyclic sugar moiety.

[0383] In one embodiment, at least one bicyclic sugar moiety is a locked nucleic acid (LNA) or a constrained ethyl (cEt) nucleoside.

[0384] In one embodiment, at least one sugar moiety is a sugar substitute.

[0385] In one embodiment, the at least one sugar substitute is a morpholino.

[0386] In one embodiment, the at least one morpholino is a modified morpholino.

[0387] In one embodiment, the SSO comprises at least one internucleoside N3' to P5' phosphorothioate linkage.

[0388] In one embodiment, the modified oligonucleotide comprises at least one internucleoside phosphorothioate linkage.

[0389] In one embodiment, all internucleoside linkages are phosphorothioate.

[0390] In the Examples section, the SSO tested was a 25 nt long phosphorothioate RNA oligonucleotide with a 2'-O-methyl modification on each sugar moiety.

[0391] In one embodiment, the SSO is conjugated to a delivery element, such as selected from the group consisting of Gal-Nac, (poly)unsaturated fatty acids (such as oleoyl and linolenoyl), anisamide, anandamide, folic acid (FolA), carbachol, estrone, Retro-1, phospholipids, α-tocopherol (α-TP), cholesterol, squalene (SQ), unbranched fatty acids (such as lauroyl, myristoyl, palmitoyl, stearoyl and behenoyl) and cell penetrating peptides.

[0392] The composition can be used to treat a specific disease. Thus, in one embodiment, the composition is used to treat or alleviate a disease selected from the group consisting of cancer, inflammatory diseases, neurodegenerative or neurological diseases, metabolic conditions, chronic liver disease and inherited retinal dystrophy (IRD).

[0393] In one embodiment, the disease is cancer, and the gene sequence is selected from ROCK1, TXNRD1, SLC7A11, STAT5B, MAPKAPK5, ZYG11A, MCCC2, SMYD2, DIAPH3, COPS3, SNX5, YBX1, CHD1L, PTPN11, UBAP2L, RNF115, HGS, TLK1, WWTR1, HMGCS1, SND1, THOC2, E2F3, LRIG2, HSP The group consisting of G2, SLC2A1, KNTC1, FDFT1, SMC1A, HIF1A, CSPP1, TRPM7, DDR2, STAG2, ORC1, TAF2, LRP6, MELK, TTBK2, TTK, ITGBL1, ROCK2, TASP1, FLT1, ZNF558, PMPCB, DBI, RAP1GDS, BUD1, CD44, CDKL5, ZNF558, RBPJ, EFEMP1, and FLT1,

[0394] or

[0395] The disease is an inflammatory disease, and the gene sequence is selected from the group consisting of DDR2 TRPM7, SMAD2, and LRP6;

[0396] or

[0397] The disease is a neurodegenerative or neurological disease, and the gene sequence is selected from the group consisting of ROCK1, OGA, TMEM97, PICALM, E2F3, SLC2A13, ASIC1, TRPM7, LRIG2, LRRK2, UBAP2L, SMC1A, TTBK2, ATXN7, CLCN1;

[0398] or

[0399] - the disease is a chronic liver disease, and the gene sequence is selected from the group consisting of SMAD2 and TRPM7, DDR2, HIF1A and ROCK1, RAP1GDS1;

[0400] or

[0401] - The disease is diabetes, and the gene sequence is selected from the group consisting of TXNRD1, DYRK1A, TRPM7 and PHLPP1.

[0402] Some optimal site target sequences for SSOs are provided in the Examples section (Table 1 and Table 3 and Table 6 and Table 7). Thus, in one embodiment, the composition for use comprises an SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0403] o A nucleic acid according to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0404] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0405] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125, and 137-201.

[0406] In a preferred embodiment, the composition for use comprises a SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0407] - a nucleic acid according to any one of SEQ ID NOs: 79-100; or

[0408] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 79-100;

[0409] or

[0410] - a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 79-100.

[0411] In a more preferred embodiment, the composition for use comprises a SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0412] - a nucleic acid according to any one of SEQ ID NOs: 79-85; or

[0413] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 79-85;

[0414] or

[0415] - a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 79-85. In one embodiment, the SSO is selected from the group consisting of:

[0416] - a nucleic acid according to any one of SEQ ID NOs: 127-136; or

[0417] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 127-136;

[0418] or

[0419] - a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 127-136.

[0420] In another preferred embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0421] o a nucleic acid according to any one of SEQ ID NOs: 100, 114, 118, 150 and 151;

[0422] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 100, 114, 118, 150 and 151; or

[0423] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 100, 114, 118, 150 and 151.

[0424] In another preferred embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0425] o a nucleic acid according to any one of SEQ ID NO: 12, 24 or 26;

[0426] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NO: 12, 24 or 26; or

[0427] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NO: 12, 24 or 26.

[0428] Preferably, the SSO is SEQ ID NO: 128 or 136. These SSOs have been optimized within the optimal site region as shown in Examples 9 and 10. Thus, by moving the binding region, for example by only 1 or 2 positions, the efficiency can surprisingly be further increased.

[0429] Other compositions used

[0430] In another aspect, the present invention relates to a composition for use as a medicament, comprising:

[0431] - A SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0432] o a nucleic acid according to any one of SEQ ID NOs: 79, or 1-26 or 80-125; or

[0433] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 79, or 1-26, or 80-125; or

[0434] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 79, or 1-26, or 80-125;

[0435] or

[0436] - An SSO selected from the group consisting of:

[0437] o a nucleic acid according to any one of SEQ ID NOs: 127-136; or

[0438] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 127-136; or

[0439] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 127-136.

[0440] Preferably, the SSO is SEQ ID NO: 128 or 136. These SSOs have been optimized within the optimal site region as shown in Examples 9 and 10. Thus, by moving the binding region, for example by only 1 or 2 positions, the efficiency can surprisingly be further increased.

[0441] As shown in Examples 9 and 10, SSOs targeting TRPM7 and HIF1A have been optimized within the optimal site region.

[0442] Similarly, optimization data for SMAD2 and LRRK2 are shown in Examples 3 and 13, respectively.

[0443] Thus, by moving the binding area just 1 or a few positions, the efficiency can surprisingly be increased further.

[0444] As also described above and in the Examples section, various genes have been targeted using the selection criteria according to the present invention (Table 1 and Table 6), or have been identified as targeting sequences using the selection criteria according to the present invention (Table 3 and Table 7). Thus, in one embodiment, the SSO is complementary or substantially complementary to a region within the nucleic acid of the SEQ ID NOs listed in Table 1, Table 3, Table 6 and Table 7 (the best site region).

[0445] In one embodiment, the SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3, wherein the gene is selected from the group consisting of: TXNRD1, SLC7A11, STAT5B, MAPKAPK5, ZYG11A, ROCK1, MCCC2, SMYD2, DIAPH3, COPS3, SNX5, YBX1, CHD1L, PTPN11, UBAP2L, RNF115, HGS, TLK1, WWTR1, HMGCS1, SND1, HIF1A, CSPP1, TAF2, ORC1, THOC2, LRP6, MELK, TTBK2, TTK, ITGBL1, ROCK2, TASP1, FLT1, KNTC1, SMC1A, ZNF558, PMPCB and DBI; for treating cancer.

[0446] In another embodiment, the SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and Tables 6 and 7, wherein the gene is selected from the group consisting of ROCK1, E2F3, LRIG2, HSPG2, SLC2A1, KNTC1, DIAPH3, FDFT1, THOC2, SMC1A, DDR2, LINGO2, TRPM7, STAG2, RAP1GDS, BUD1, CD44, CDKL5, RNF115, UBAP2L, ZNF558, RBPJ, EFEMP1, FLT1; for treating cancer.

[0447] In another embodiment, the SSO is complementary or substantially complementary to a SEQ ID NO listed in Table 1 and Table 3 and Table 6 and Table 7, wherein the gene is selected from the group consisting of: ROCK1, OGA, TMEM97, PICALM, LRRK2, UBAP2L, SMC1A and TTBK2; for treating a neurological disease.

[0448] In an even more preferred embodiment, the neurological disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Frederick's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease and spinal muscular atrophy.

[0449] Neurodegenerative diseases are progressive loss of neuronal structure or function, including neuronal death. Many neurodegenerative diseases—including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, and prion diseases—occur as a result of a neurodegenerative process.

[0450] In one embodiment, the SSO is complementary or substantially complementary to a SEQ ID NO listed in Tables 1 and 3 and Tables 6 and 7, wherein the gene is selected from the group consisting of ROCK1, E2F3, SLC2A13, LINGO2, TRPM7, ASIC1, LRIG2, LRRK2, UBAP2L, SMC1A, ATXN7 and CLCN1; for treating a neurological disease.

[0451] Likewise, in an even more preferred embodiment, the neurological disease is selected from the group consisting of Alzheimer's disease, amyotrophic lateral sclerosis, Frederick's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease and spinal muscular atrophy.

[0452] In one embodiment, the SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and Tables 6 and 7, wherein the gene is selected from the group consisting of: TXNRD1, DYRK1A, TRPM7 and PHLPP1; for treating diabetes. In a preferred embodiment, diabetes is selected from type 1 diabetes and type 2 diabetes.

[0453] In another embodiment, the SSO is complementary or substantially complementary to the SEQ ID NOs listed in Tables 1 and 3 and 6 and 7, wherein the gene is selected from the group consisting of LINGO2, SMAD2, ORC1, DDR2, STAG2, TRPM7, HIF1A, HTT, TAF2, CSPP1, RN115, LRRK2, UBAB2L, LRP6, MELK and KNTC1. These 16 genes all contain pseudoexons that meet all criteria, are activated by SSOs located in the optimal site region (see Tables 1 and 3 and 6 and 7), and have high therapeutic potential.

[0454] Composition

[0455] In yet another aspect, the present invention relates to

[0456] - A composition comprising an SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0457] o A nucleic acid according to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0458] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125 and 137-201; or

[0459] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 106, 1-26, 79-105, 107-125, and 137-201;

[0460] or

[0461] - A composition comprising an SSO selected from the group consisting of:

[0462] - a nucleic acid according to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216; or

[0463] - a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216; or

[0464] - a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 127-136 and SEQ ID NOs: 202-216.

[0465] In one aspect, the SSO is selected from the group of SSOs listed in Table 4 (see Example 9), Table 5 (see Example 10), and Table 8 (see Example 11).

[0466] As mentioned above, such a composition can be used as a medicament, for example for the treatment of the above listed list of diseases.

[0467] In another aspect, the present invention relates to a composition comprising a splice switching oligonucleotide (SSO), the composition comprising

[0468] - A SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0469] o a nucleic acid according to any one of SEQ ID NOs: 217-294;

[0470] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 217-294; or

[0471] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 217-294;

[0472] or

[0473] - An SSO selected from the group consisting of:

[0474] o a nucleic acid according to any one of SEQ ID NOs: 295-367; or

[0475] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 295-367; or

[0476] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 295-367.

[0477] Allele-specific targeting - SNPs in the optimal locus region

[0478] By using the method according to the invention, the present team has identified SNPs within the optimal site region of the LRRK2 pre-mRNA (see also Example 13).

[0479] By careful design of the SSO, it is believed that this is reliable, i.e., such allele-specific SSOs can be used to preferentially target pathogenic pre-mRNA (from the pathogenic allele), while pre-mRNA from the "normally functioning" allele is unaffected (or less affected).

[0480] Therefore, by using this approach, it is possible to maintain a certain amount of normal RNA and thus maintain normal gene function.

[0481] As can be seen from Example 13, SEQ ID NOs: 141 and 142 will target one SNP-specific allele, while SEQ ID NOs: 158 and 159 will target another SNP-specific allele.

[0482] Thus, in one embodiment, a composition according to the invention is administered to a subject that is heterozygous in a region of the pre-mRNA targeted by the SSO, resulting in the SSO having increased binding affinity for the pre-mRNA of one of the alleles, thereby providing increased splice switching activity in said allele.

[0483] In another embodiment, the pre-mRNA encodes LRRK2.

[0484] In another embodiment, the pre-mRNA encodes LRRK2 and the subject is heterozygous at position rs17444202.

[0485] In another embodiment, the pre-mRNA encodes LRRK2, and the subject is heterozygous for a pathogenic mutation in LRRK2.

[0486] In another embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0487] o a nucleic acid according to any one of SEQ ID NOs: 141, 142, 158 and 159; or

[0488] o A nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 141, 142, 158 and 159; or

[0489] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 141, 142, 158 and 159;

[0490] or

[0491] - The SSO is selected from the group consisting of:

[0492] o a nucleic acid according to any one of SEQ ID NOs: 208-216; or

[0493] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 208-216; or

[0494] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 208-216.

[0495] In one embodiment, the SSO promotes a greater inclusion of the pseudoexon for the pathogenic allele compared to the other allele. Likewise, this allows the normal mRNA to be present to a greater extent. Thus, the SSO has an increased binding affinity for the pre-mRNA of the pathogenic allele.

[0496] Another aspect of the invention relates to a method for identifying a subject who may meet criteria for allele-specific targeting of a dysfunctional LRRK2 allele, the method comprising

[0497] - determining the allelic status of LRRK2 in a DNA sample from the subject;

[0498] wherein if the subject is heterozygous for rs17444202, the subject meets the criteria for allele-specific treatment according to the present invention; or

[0499] Wherein if the subject is not heterozygous for rs17444202, the subject does not meet the criteria for allele-specific treatment according to the present invention.

[0500] As also outlined further below, a subject may also be homozygous for a SNP and therefore contain the SNP on both alleles, which may promote false exon inclusion. This may not be preferred, but if the alternative is no treatment, it may be a better option.

[0501] Allelic status can be determined by Sanger or next-generation (NGS) sequencing or mutation-specific assays such as ARMS or Taq-man.

[0502] Allele-specific targeting - SNPs in splice sites

[0503] The present invention team has identified a wide range of SNPs present in the splice sites of pseudoexons. When the SNP is present in one or both alleles, a subject carrying such a SNP may meet the criteria for allele-specific SSO treatment (if the subject contains the SNP only in the allele carrying the pathogenic gene), or if the subject is homozygous for the SNP and therefore carries the SNP on both alleles. In other words, the present invention team has identified a SNP that increases the MaxEnt score of the splice site, making it possible (or improved) for pseudoexon inclusion when treated with the corresponding SSO targeting the pseudoexon. See also Examples 15-16.

[0504] Thus, one aspect of the present invention relates to a composition comprising a splice switching oligonucleotide (SSO) for use as a medicament, the composition comprising

[0505] - A SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0506] o a nucleic acid according to any one of SEQ ID NOs: 217-294;

[0507] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 217-294; or

[0508] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 217-294;

[0509] or

[0510] - An SSO selected from the group consisting of:

[0511] o a nucleic acid according to any one of SEQ ID NOs: 295-367; or

[0512] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 295-367; or

[0513] o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 295-367;

[0514] wherein the SSO is complementary or substantially complementary to a target pre-mRNA, the target pre-mRNA comprising:

[0515] - Functionally disabling pseudoexons, including:

[0516] o 3' splice site at the 5' end; and

[0517] o 5' splice site at the 3' end;

[0518] The SSO is complementary or substantially complementary to the target pre-RNA in the region +9 to +39 downstream of the 5' splice site of the pseudo exon.

[0519] As shown in Example 16, a large range of SNPs have been identified that allow SSO-based pseudoexon inclusion therapy.

[0520] In one embodiment, the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of:

[0521] o a nucleic acid according to any one of SEQ ID NO: 217;

[0522] o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NO: 217; or

[0523] o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NO:217.

[0524] Example 15 shows that when a specific SNP is present, an SSO targeting SEQ ID NO: 217 is able to direct the inclusion of a pseudoexon into the mature mRNA.

[0525] In one embodiment, the composition is used to treat a human subject suffering from a disease or condition characterized by increased expression or altered function of a functional protein that causes or affects the condition, or in which decreased expression of a functional gene product is therapeutically beneficial.

[0526] In another embodiment, the SSO comprises a sequence that is substantially complementary to a polynucleotide in a pre-mRNA, comprising at most 3 mismatches, such as at most 2 mismatches or such as at most 1 mismatch.

[0527] In another embodiment, the length of the SSO is in the range of 9-100 nucleotides, such as 9-50 nucleotides, preferably in the range of 9-40 nucleotides, more preferably in the range of 9-31 nucleotides or 9-25 nucleotides.

[0528] In another embodiment, the SSO comprises a sequence that is complementary or substantially complementary to a polynucleotide in a pre-mRNA as defined above, wherein the length of the sequence is in the range of 9-31 nucleotides, such as 9-20 nucleotides, preferably the sequence is complementary in the range of 9-31 nucleotides, such as 9-20, or such as 20-31 nucleotides, such as 25-31 nucleotides.

[0529] In one embodiment, the SSO comprises one or more artificial nucleotides, such as sugar-modified nucleotides.

[0530] In one embodiment, the oligonucleotide does not mediate RNase H-mediated mRNA degradation.

[0531] In one embodiment, at least one modified sugar moiety is a 2'-substituted sugar moiety.

[0532] In one embodiment, the 2'-substituted sugar moiety has a 2'-substitution selected from the group consisting of 2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), and 2'-O-methoxyethyl (2'-MOE).

[0533] In one embodiment, the composition is used to treat or alleviate a disease selected from the group consisting of cancer, inflammatory diseases, neurodegenerative or neurological diseases, metabolic conditions, chronic liver diseases, and inherited retinal dystrophy (IRD).

[0534] As shown in Example 15, the presence of the SNP allows the SSO to promote the inclusion of the functionally disabling pseudoexon in the pathogenic allele to a greater extent than other alleles. Thus, in one embodiment, the composition is administered to a subject that is heterozygous for the sequence variation (SNP) in the pre-mRNA targeted by the SSO, whereby the SSO promotes the inclusion of the functionally disabling pseudoexon in the pathogenic allele to a greater extent than other alleles.

[0535] The subject may also be homozygous. In this case, both the "healthy gene" and the diseased gene will be subject to pseudoexon inclusion. It is of course also possible for the subject to have two diseased genes (one on each allele). Thus, in one embodiment, the composition is administered to a subject who is homozygous for the SNP variation (SNP) in the pre-mRNA targeted by the SSO.

[0536] In one embodiment, the subject is heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site, preferably the 5' splice site, that functionally disables the pseudoexon.

[0537] In one embodiment, the SNP is a point mutation, an insertion (such as an insertion of 1-20 nucleotides at the SNP position) or a deletion (such as a deletion of 1-20 nucleotides at the SNP position).

[0538] In one embodiment, the insertion is 1-10 nucleotides, such as 1-5 nucleotides, such as 2-4 nucleotides or 2-3 nucleotides. In another embodiment, the deletion is 1-10 nucleotides, such as 1-5 nucleotides, such as 2-4 nucleotides or 2-3 nucleotides.

[0539] In another embodiment, the SNP is located at the (23-mer) 3' splice site (-20 to +3 nt of an intron-exon boundary) or the (9-mer) 5' splice site (-3 to +6 nt of an exon-intron boundary).

[0540] In another embodiment, heterozygosity in the pathogenic gene increases the inclusion of the pseudoexon of one allele in the mature mRNA to a greater extent than the corresponding (normally functioning) gene on the other allele when contacted with an SSO.

[0541] In another embodiment, heterozygosity in the pathogenic gene increases the MaxEnt score of the splice site of the pseudoexon in the pathogenic gene compared to the corresponding (normally functioning) gene on the other allele. As described above, the MaxEnt score is a fixed number, calculated by a specific algorithm.

[0542] In a related embodiment, heterozygosity in the pathogenic gene results in a higher MaxEnt score for the splice site of the pseudoexon in the pathogenic gene compared to the corresponding (normally functioning) gene on the other allele.

[0543] In another embodiment, a splice site of a pseudoexon in a pathogenic gene allele has a higher MaxEnt score than the corresponding splice site of the (normally functioning) gene on the other allele.

[0544] There is a database that uniquely identifies SNPs with IDs. Thus, in one embodiment, the subject has a SNP in a pathogenic allele selected from the group of SNP IDs according to Table 9. Likewise, the SNP may also be present on both alleles. Thus, in one embodiment, the subject has a SNP on both alleles selected from the group of SNP IDs according to Table 9.

[0545] In a more specific embodiment, the subject has a SNP in the causative allele selected from the group of SNPs according to Table 9, and the SSO targets the corresponding optimal site sequence according to Table 9.

[0546] In one embodiment, the corresponding SSO is selected from Table 10.

[0547] In one embodiment, the pre-mRNA encodes LRRK2. See also Examples 15 and 16.

[0548] In another embodiment, the pre-mRNA encodes LRRK2 and the subject has a high MaxEnt score "G allele" of SNP rs10878372 in the pathogenic LRRK2 allele.

[0549] In one embodiment, the pre-mRNA encodes LRRK2, and the subject is heterozygous for a pathogenic mutation in LRRK2.

[0550] It will be appreciated that the targeted pseudoexon may be located in a gene that is located on either the X or Y chromosome, in which case male subjects cannot be considered heterozygous or homozygous since they only contain one chromosome, X and Y. However, these subjects may also be treated according to the present invention.

[0551] As outlined throughout the application, the present invention also relates to a composition, such as a pharmaceutical composition, comprising a SSO according to the present invention.

[0552] Methods for identifying subjects meeting criteria for allele-specific SSO-based pseudoexon inclusion treatment

[0553] The present invention can also be used to identify subjects who meet the criteria for pseudoexon inclusion therapy based on allele-specific SSOs. Therefore, one aspect of the present invention relates to a method for identifying subjects who may meet the criteria for pseudoexon inclusion therapy based on allele-specific SSOs of a dysfunctional gene or a pathogenic gene, the method comprising

[0554] - determining the presence or absence of heterozygosity in a pseudoexon of a dysfunctional gene or a disease-causing gene in a biological sample from the subject;

[0555] wherein if the subject is heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site, preferably in the 5' splice site, of the functionally disabling pseudoexon, then the subject may meet the criteria for allele-specific SSO-based pseudoexon inclusion treatment; or

[0556] wherein if the subject is not heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site of the functionally disabling pseudoexon, the subject may not meet criteria for allele-specific SSO-based pseudoexon inclusion treatment;

[0557] Wherein the SSO is complementary or substantially complementary to a target pre-mRNA of a dysfunctional gene or a disease-causing gene, the target pre-mRNA comprising:

[0558] - Functionally disabling pseudoexons, including:

[0559] o 3' splice site at the 5' end; and

[0560] o 5' splice site at the 3' end.

[0561] As outlined in Examples 15 and 16, in some cases, the SSO only works if the subject has the SNP, e.g., according to Table 9.

[0562] In one embodiment, the allele-specific SSO-based pseudoexon-containing treatment causes the SSO to hybridize with the pre-mRNA in vivo, and the pseudoexon of the dysfunctional gene or pathogenic gene becomes part of the mature mRNA to a greater extent than the corresponding pre-mRNA not contacted with the SSO.

[0563] In another embodiment, the allele-specific SSO-based pseudoexon comprises a treatment that causes the SSO to hybridize with a pre-mRNA in vivo, and the pseudoexon in the allele having a dysfunctional gene or a pathogenic gene becomes part of the mature mRNA to a greater extent than the corresponding pre-mRNA not contacted with the SSO.

[0564] In another embodiment, when / if contacted with an SSO, heterozygosity for a sequence variation (SNP) in the 5' splice site and / or 3' splice site of the pseudo-exon in the pre-mRNA targeted by the SSO will promote the pathogenic allele to include a functionally disabling pseudo-exon to a greater extent compared to other alleles.

[0565] In one embodiment, heterozygosity for the sequence variation (SNP) is at the 5' splice site and / or the 3' splice site, preferably the 5' splice site, which functionally disables the pseudoexon.

[0566] In one embodiment, the heterozygosity of the sequence variation (SNP) in the disease-causing gene is a point mutation (SNP), an insertion of 1-20 nucleotides or a deletion of 1-20 nucleotides, preferably a point mutation.

[0567] In one embodiment, when / if contacted with an SSO, the causative gene increases inclusion of the pseudoexon to a greater extent than the corresponding (normally functioning) gene on the other allele.

[0568] In one embodiment, heterozygosity for a sequence variation (SNP) in a causative gene increases the MaxEnt score of a splice site compared to the corresponding splice site of the gene on the other allele (which functions normally).

[0569] In one embodiment, heterozygosity for a sequence variation (SNP) in a causative gene results in a higher MaxEnt score for a splice site compared to the corresponding splice site in the (normally functioning) gene on the other allele.

[0570] In one embodiment, heterozygosity for a sequence variation (SNP) in a pathogenic gene is in a splice site of a pseudoexon of the pathogenic gene, resulting in a higher MaxEnt score compared to the corresponding splice site of the (normally functioning) gene on the other allele.

[0571] In one embodiment, allele-specific SSO-based pseudoexon inclusion therapy comprises therapy with an SSO that hybridizes in vivo to a greater extent to pre-mRNA of an allele having a pathogenic allele than to an allele not having the pathogenic allele, when the SSO hybridizes in vivo to pre-mRNA.

[0572] In one embodiment, the SSO is complementary or substantially complementary to the target pre-RNA in the region +9 to +39 downstream of the 5' splice site of the pseudoexon.

[0573] In one embodiment, the target sequence of the SSO is located in a gene selected from the group consisting of LRRK2, LMN1B and ATXN2.

[0574] In one embodiment, the subject has a SNP in a causative allele selected from the group of SNP IDs according to Table 9.

[0575] In one embodiment, the subject has a SNP in two alleles selected from the group of SNP IDs according to Table 9.

[0576] In one embodiment, the allelic state is determined by a method selected from the group consisting of, for example, Sanger sequencing, next generation sequencing (NGS), and mutation-specific assays (such as ARMS and Taq-man). A skilled person may find other methods suitable for determining the allelic state.

[0577] As also described above, a subject may be homozygous or heterozygous for a SNP (or the SNP may be X or Y chromosome associated). Thus, another aspect of the invention relates to a method for identifying a subject who may meet criteria for SSO-based pseudoexon inclusion treatment of a dysfunctional or pathogenic gene, the method comprising

[0578] - determining the presence or absence of a SNP in a pseudoexon of a dysfunctional gene or a disease-causing gene in a biological sample from the subject, which enables SSO-based pseudoexon inclusion therapy;

[0579] wherein if the subject has a sequence variation (SNP) at the 5' splice site and / or the 3' splice site, preferably the 5' splice site, of the functionally disabling pseudoexon, then the subject may meet the criteria for SSO-based pseudoexon inclusion treatment; or

[0580] wherein if the subject does not have a sequence variation (SNP) at the 5' splice site and / or the 3' splice site of the functionally disabling pseudoexon, the subject may not meet the criteria for SSO-based pseudoexon inclusion therapy;

[0581] o Wherein the SSO is complementary or substantially complementary to a target pre-mRNA of a dysfunctional gene or a disease-causing gene, wherein the target pre-mRNA comprises:

[0582] - Functionally disabling pseudoexons, including:

[0583] o 3' splice site at the 5' end; and

[0584] o 5' splice site at the 3' end.

[0585] In one embodiment, the subject is heterozygous for the SNP or homozygous for the SNP, or the SNP is X or Y chromosome associated, preferably heterozygous.

[0586] Computer Implementation

[0587] In one aspect, the present invention relates to a computer program product suitable for enabling a computer system comprising at least one computer having data storage means connected thereto to control a method according to one or more aspects of the invention, such as a computer program product comprising instructions which, when the program is executed by a computer, cause the computer to perform [the steps of] the method of the invention.

[0588] This aspect of the invention is particularly, but not exclusively, advantageous because the invention can be implemented by a computer program product that enables a computer system to perform the operations of the apparatus / system of aspects of the invention when downloaded or uploaded to a computer system. Such a computer program product can be provided on any kind of computer readable medium, or provided over a network.

[0589] Each aspect of the invention may be individually combined with any other aspects and embodiments. These and other aspects of the invention will become apparent from the following description, with reference to the described embodiments.

[0590] Although the present invention has been described in conjunction with specific embodiments, it should not be interpreted as being limited in any way to the embodiments presented. The scope of the present invention will be interpreted in accordance with the appended set of claims. In the context of the claims, the terms "comprise" or "include" do not exclude other possible elements or steps. In addition, references such as "one" or "a kind" should not be interpreted as excluding multiple. The use of reference symbols in the claims with respect to elements shown in the drawings should also not be interpreted as limiting the scope of the present invention. In addition, the individual features mentioned in different claims may be advantageously combined, and the mention of these features in different claims does not exclude that the combination of features is impossible and advantageous.

[0591] All patent and non-patent references cited in this application are incorporated herein by reference in their entirety.

[0592] The present invention will now be described in further detail in the following non-limiting examples.

[0593] Example

[0594] Example 1 - Summary of the Invention

[0595] FIG. 1 and the corresponding legends summarize the basic principles behind the present invention. Pseudo-exons are intronic sequences flanked by 3' and 5' splice sites. Since the amount of pseudo-exons contained in mRNA transcripts is generally low, and because the decay of nonsense-mediated mRNA (NMD) systems often degrades mRNA containing pseudo-exons, pseudo-exons are generally not identified. The best site region is defined as a region of +9 to +39 nucleotides downstream of the 5' splice site of the pseudo-exon, meeting the criteria described in this application (see, e.g., Example 2). By using an SSO complementary to the best site region of pseudo-exons that meet the criteria, pseudo-exons can be activated and increased to be included in mRNA transcripts. Pseudo-exons are included in mRNA and will regulate gene expression at the mRNA level or protein level by mislocalization, destabilization and degradation or changes in protein function. 5'ss: 5' splice site, 3'ss: 3' splice site, SSO: splice conversion oligonucleotide.

[0596] Figure 2 We show how RNA sequencing data can be used to detect double-junctions of in vivo splicing for the empirical detection of pseudo-exons that are included at low levels in endogenous transcripts.

[0597] After mapping to the human genome, the reads are filtered to retain only fragments containing at least two splice junctions. The splice junctions of the entire fragment are then assembled into an exon structure so that there is an unmapped gap of up to 100 bp between the reads in the fragment. The exons are then classified using known exon annotations to identify pseudoexons contained in introns. Pseudoexons that may be candidates for activation by SSO binding to the optimal site region can be identified by the criteria according to the present invention, and highly therapeutically relevant pseudoexons can then be identified in genes where downregulation or alteration of expression of the functional gene product is medically relevant. Subsequently, the SSO can be prepared using standard synthesis.

[0598] Example 2 - Identification of SSO selection parameters

[0599] Purpose

[0600] Direct targeting of specific genes as part of the suppression of pathogenic mRNA or protein associated with a disease. By activating pseudoexons in the target gene of interest, the resulting mRNA product will be degraded through the NMD pathway, or mislocalized or destabilized, or translated into a non-functional, unstable or mislocalized protein or one with altered function. Our goal was to use splice-switching antisense oligonucleotides (SSOs) to include pseudoexons in the mRNA transcript of the targeted gene. This strategy is superior to existing therapies targeting multiple proteins because the risk of off-target effects is minimized when using sequence-specific SSOs that are modified to achieve increased stability and binding specificity to their target sequence in the primary RNA transcript. Here, our goal was to identify pseudoexons that can be activated so that they can be spliced ​​into the mRNA by using SSOs that bind to the +9 to +39 region (called the optimal site region) downstream of the pseudoexon donor site (5'-splice site) and to establish criteria that describe these pseudoexons as distinct from non-activated pseudoexons.

[0601] Materials and Methods

[0602] We used public RNA sequencing data (Geuvadis, E-MTAB-2836, E-MTAB-513, GSE52946 and GSE124439) and mapped them with STAR after excising aptamer contamination and low-quality bases with bbduk. HeLa cells were seeded in 12-well plates and forward transfected with 20 or 40 nM of 2'-O-methyl SSO with a full thiophosphate backbone at 60% confluence using Lipofectamine RNAiMAX (invitrogen). The non-binding control SSO (5'GCUCAAUAUGCUACUGCCAUGCUUG3') (SEQ ID NO: 126) was used as a control. RNA was collected 48 hours later, and RNA was isolated using Trizol (Invitrogen) and chloroform, followed by isopropanol precipitation. Complementary DNA (cDNA) was synthesized from 500 ng RNA using a high-capacity cDNA kit (Applied Biosystems). Primers were designed to span at least one exon-exon junction of adjacent exons flanking the pseudoexon of interest. PCR was performed using TEMPase hot start DNA polymerase (ampliqon) and 1 μl cDNA per reaction. 0.5 pmol / μl of each primer was used. PCR products were separated on 2% Seakem LE (Lonza) TBE agarose gels at 80 V for 1 hour.

[0603] The optimal site region is located from +9 to +39 of the 5' splice site of the pseudoexon.

[0604] All SSOs are 25 nt long phosphorothioate RNA oligonucleotides with 2'-O-methyl modifications on each sugar moiety (produced by LGC Biosearch Technologies). The SSOs are used to target positions +11 to +35 within the optimal site region of the gene (relative to the 5' splice site of the pseudoexon). Therefore, the SSOs bind within the optimal site.

[0605] result

[0606] To identify pseudoexons across multiple tissues, we collected publicly available RNA sequencing data representing many different cell types. After mapping to the human genome, we filtered reads from all fragments containing at least two splice junctions. We then mapped splice junctions across the entire fragment, leaving unmapped gaps of up to 100 bp between reads in the fragment. From this we compiled a non-degenerate list of fully spliced ​​exons, from which we extracted unknown exons contained within introns. Using this double-join approach, we were able to identify fully spliced ​​pseudoexons, even at very low expression levels. We tested 78 SSOs in the optimal site region from +11 to +35 downstream of randomly selected pseudoexons identified in targeted RNA sequencing data. 26 of these SSOs were able to increase pseudoexon inclusion in the mRNA transcripts of the targeted genes (Table 1 below), while the remaining 52 SSOs had no effect on pseudoexon inclusion (Table 2 below).

[0607] Table 1: There were 26 pseudoexons that met all criteria, all of which were activated by SSOs located in the optimal site region.

[0608] The best site regions were annotated by their genomic sequence (DNA).

[0609]

[0610]

[0611] Underlined SSO binding sequences that have been tested or preferred. Binding to the corresponding pre-mRNA. The hg38 genome coordinates follow the BED format; 0-based start coordinates and 1-based end coordinates.

[0612] Table 2: There were 52 pseudoexons that did not meet all criteria and were not activated by SSOs located in the optimal site region.

[0613]

[0614]

[0615]

[0616] Underlined SSO binding sequences tested or preferred. Binding to the corresponding pre-mRNA. hg38 genomic coordinates follow the GFF / GTF format; 1-based start and end coordinates.

[0617] Based on these results, we established a set of criteria that must be met in order for a pseudoexon to be included by an SSO targeting the optimal site region. Using these criteria, we have selected novel targets for pseudoexon inclusion in pathogenic genes with high potential for therapeutic applications in human disease.

[0618] standard:

[0619] For pseudoexons:

[0620] Pseudoexon length <160 nt;

[0621] Pseudoexon length > 30 nt;

[0622] ●The last 3 nt of the pseudoexon is different from TAG;

[0623] MaxEnt score of the donor splice site ≥ 4.33;

[0624] MaxEnt score of the donor splice site ≤10.06; and

[0625] The MaxEnt score of the receptor splice site is ≥3.63;

[0626] For the gene sequence +9 to +39 downstream of the 5' splice site of the pseudoexon (3):

[0627] Total pyrimidines ≤ 20;

[0628] Total thymidine bases ≤ 12;

[0629] Total thymidine bases ≥ 4;

[0630] Total guanine bases ≤ 12;

[0631] The maximum length of thymidine polymer is ≤ 4;

[0632] The maximum length of pyrimidine polymer is ≤10;

[0633] The minimum length of purine polymer is ≥ 3; and

[0634] The maximum number of guanine polymers of at least 3 nt in length is ≤ 2.

[0635] in conclusion

[0636] Pseudoexons in target genes of interest can be activated as a mechanism to downregulate disease-causing proteins. By filtering pseudoexons based on the criteria we have established, selection of new target candidates will enable the discovery of new therapeutic agents.

[0637] Example 3 - SMAD2

[0638] Purpose

[0639] Chronic liver diseases are characterized by inflammation and fibrosis of the liver. Through in silico analysis and in vivo experiments, we aimed to investigate the presence of pseudoexons in the TGF-β / Smad signaling pathway, which is important for tissue fibrosis (Inagaki et al., 2007).

[0640] Materials and Methods

[0641] We used our new double ligation method to identify fragments with completely spliced ​​pseudo exons in publicly available RNA-seq data from the GEUVADIS project. HeLa cells, LX-2 and HepG2 cells were seeded in 12-well plates and forward transfected with 40nM SSO at 60% fusion using Lipofectamine RNAiMAX (invitrogen). SSO (targeting SEQ ID NO: 21; specific target sequences are underlined in SEQ ID NO: 21 of Table 1) is a 25nt long thiophosphate RNA oligonucleotide with a 2'-O-methyl modification in each sugar moiety (produced by LGC Biosearch Technologies). (See also the table in Example 2). SSO is complementary to the +11 to +35 positions within the optimal site region of the SMAD2 gene (relative to the 5' splice site of the pseudo exon) (SEQ ID NO: 21). Therefore, SSO is bound within the optimal site. To determine the optimal SSO targeting the sweet spot region, we tested several SSOs using a 25 nt long SSO targeting the sweet spot region at positions +9 to +14 downstream of the PE 5'ss (SEQ ID NOs: 202-207, listed in Table 8 of Example 11).

[0642] A non-binding SSO (5'-GCUCAAUAUGCUACUGCCAUGCUUG-3') (SEQ ID NO: 126) with similar modifications was used as a negative control. For experiments stimulated with TGFβ, cells were stimulated with 10ng / ml TGFβ (R&D systems) for 16 hours before collecting RNA and protein. RNA was collected 48 hours later and isolated using Trizol (Invitrogen) and chloroform, followed by isopropanol precipitation. Complementary DNA (cDNA) was synthesized from 500ng RNA using a high-capacity cDNA kit (Applied Biosystems). Primers were designed to span at least one exon-exon connection of adjacent exons flanking the pseudoexon of interest. PCR was performed using TEMPase hot-start DNA polymerase (ampliqon) and 1μl cDNA per reaction. 0.5pmol / μl was used for each primer. PCR products were separated at 80V for 1 hour on a 2% Seakem LE (Lonza) TBE agarose gel. Proteins were extracted by lysing cells with okaidic acid to preserve phosphorylated proteins, treated with benzonase, and denatured proteins were separated on 4-12% NuPage SDS-Page gels and analyzed by Western blotting using antibodies against SMAD2, phosphorylated SMAD2, and actin as controls. For studies of myofibroblast formation, LX-2 cells were grown in 96-well plates transfected with 20 nM SSO and incubated in an Incucyte instrument, with images taken every 4 hours. Images were analyzed in ImageJ by making masks for spherical (differentiated) cells.

[0643] result

[0644] By examining fragments with fully spliced ​​pseudoexons, we identified a pseudoexon located within intron 5 of the SMAD2 gene, encoding the signaling protein Mothers for decapentaplegic homolog 2, which is involved in the TGF-β / Smad pathway. Inclusion of the pseudoexon into the mature mRNA resulted in a 46-nt insertion into the coding region, causing a frameshift. A stop codon (UAA) was also located within the pseudoexon, which may activate the NMD pathway, leading to transcript degradation.

[0645] Transfection of SSOs (SEQ ID NOs: 202-207, listed in Table 8, Example 11) showed that all mediated pseudoexon inclusion, and SSOs targeted from +11 and +12 were the best in mediating pseudoexon inclusion into SMAD2 transcripts (results not shown).

[0646] Transfection of HeLa cells with SSO complementary to positions +11 to +35 downstream of the 5' splice site resulted in up to 90% pseudo-exon inclusion (Figure 8A). Transfection of the same SSO in LX-2 hepatic stellate cells resulted in even higher pseudo-exon inclusion, using lower concentrations of SSO (Figure 8B). Protein levels from HepG2 cells showed a significant decrease in SMAD2 protein as well as phosphorylated SMAD2 under TGFβ stimulation (Figure 8C). TGFβ stimulation of LX-2 cells resulted in cell differentiation into myofibroblasts, which was reduced by transfection with +11 SSO (Figure 8D).

[0647] in conclusion

[0648] The use of specific SSOs to increase the inclusion of pseudoexons, thereby disrupting the function of the normal gene product through degradation of the transcript or expression of truncated and non-functional proteins, can reduce the normal function of the SMAD2 gene by up to 90%. This has been associated with liver fibrosis and other conditions associated with increased TGF-β activity, of which SMAD2 is a positive regulator (Sysa et al., 2009). In addition, SMAD2 downregulation can reduce the growth of gliomas (Papachristodoulou et al., 2019).

[0649] Inagaki Y et al., Gut. 2007 Feb; 56(2): 284-92. doi: 10.1136 / gut.2005.088690

[0650] Sysa P et al., 2009 Sep; 28(9): 425-34. doi: 10.1089 / dna.2009.0884

[0651] Papachristodoulou A et al., Clin Cancer Res. 2019 Dec 1; 25(23): 7189-7201. doi: 10.1158 / 1078-0432. CCR-17-3024

[0652] Example 4 - ORC1

[0653] Purpose

[0654] Origin of Recognition Complex (ORC) genes are involved in DNA replication and are highly expressed in hepatocellular carcinoma tumors (Wang et al., 2020). Low expression of ORC1 consistently indicates a better prognosis compared to high ORC1 expression (Wang et al., 2020), while knockdown of ORC1 sensitizes cancer cells, making them vulnerable to other anticancer treatments (Zimmerman et al., 2013). Through in silico analysis and in vivo experiments, we aimed to investigate the presence of pseudoexons in the ORC1 gene, which could potentially be used to downregulate the expression of this gene.

[0655] Materials and Methods

[0656] We used our new double ligation approach to identify fragments with fully spliced ​​pseudoexons in publicly available RNA-seq data from the GEUVADIS project.HeLa cells were seeded in 12-well plates and forward transfected with 40 nM SSO at 60% confluence using Lipofectamine RNAiMAX (invitrogen).

[0657] The SSO (targeting SEQ ID NO: 18; the specific target sequence is underlined in SEQ ID NO: 18 in Table 1) is a 25 nt long phosphorothioate RNA oligonucleotide with a 2'-O-methyl modification on each sugar moiety (produced by LGC Biosearch Technologies). (See also the table in Example 2). The SSO is complementary to positions +11 to +35 within the optimal site region of the ORC1 gene (relative to the 5' splice site of the pseudoexon). Thus, the SSO binds within the optimal site.

[0658] A non-binding SSO (5'GCUCAAUAUGCUACUGCCAUGCUUG3') (SEQ ID NO: 126) with similar modifications was used as a negative control. RNA was collected 48 hours later and isolated using Trizol (Invitrogen) and chloroform, followed by isopropanol precipitation. Complementary DNA (cDNA) was synthesized from 500ng RNA using a high-capacity cDNA kit (Applied Biosystems). Primers were designed to span at least one exon-exon connection of adjacent exons flanking the pseudoexon of interest. PCR was performed using TEMPase hot start DNA polymerase (ampliqon) and 1μl cDNA per reaction. Each primer used 0.5pmol / μl. PCR products were separated at 80V for 1 hour on a 2% Seakem LE (Lonza) TBE agarose gel.

[0659] result

[0660] Using our double ligation method to detect fragments with fully spliced ​​pseudo exons, we identified a pseudo exon in intron 5 of the ORC1 gene, resulting in a 62 nt insertion into the pre-mRNA, causing a frameshift. Transfection of HeLa cells with an SSO complementary to positions +11 to +35 downstream of the 5' splice site resulted in up to 45% more pseudo exon inclusion (data not shown).

[0661] in conclusion

[0662] Using specific SSOs to increase the inclusion of pseudoexons that disrupt the function of the normal gene product can reduce the normal expression of the ORC1 gene product by up to 45%. Therefore, SSO-mediated downregulation of ORC1 expression may help enhance the anticancer effects of other drugs.

[0663] Wang XK et al., J Cancer. 2020 Jan 20; 11(7): 1869-1882. doi: 10.7150 / jca.39163

[0664] Zimmerman, KM et al., Mol Cancer Res, 2013.11(4): p.370-80.

[0665] Example 5 - LINGO2

[0666] Purpose

[0667] LINGO2 (leucine-rich repeat and immunoglobulin-like domain-containing Nogo receptor-interacting protein 2) is highly expressed in many tissues, including intestinal tissue, brain, and neurons such as cortical neurons and dorsal root ganglion (DRG) neurons (Guillemain et al., 2020). LINGO2 expression is increased in gastric cancer, which is associated with poor prognosis, and downregulation of LINGO2 reduces gastric cancer cell proliferation (Jo et al., 2019). LINGO2 also negatively regulates motor neuron survival and motor neuron axon length.

[0668] This suggests that knocking down or altering LINGO2 expression could be a new therapeutic approach for neuronal disorders and cancer.

[0669] Materials and Methods

[0670] We use the analysis pipeline ( Figure 2) to analyze publicly available RNA-seq data. HeLa cells were grown in RPMI and transfected with 20 nM SSO using Lipofectamine. After 24 hours, cells were harvested and RNA was purified. RT-PCR was performed and the resulting products were visualized on 2% agarose gels. For the Incucyte experiments, U251 cells were grown in 96-well plates transfected with 5, 10, 20, or 40 nM SSO and incubated in the Incucyte instrument, with images taken every 4 hours.

[0671] result:

[0672] Based on the high expression of LINGO2 in neurons and the brain, we speculated whether SSO-based PE activation could be used to treat glioblastoma. By using an SSO targeting the optimal site region according to SEQ ID NO: 15 (the specific target sequence is underlined in SEQ ID NO: 15 in Table 1), we demonstrated high levels of inclusion of the LINGO2 pseudoexon at chr 9: 28370208-28370262 (-) in U251 glioblastoma cells ( Figure 3A ). This pseudoexon introduced 55 bp between exon 3 and 4 in the pseudoexon mRNA. When U251 glioblastoma cells were studied with this SSO, we observed that SSO treatment resulted in a dose-dependent reduction in the growth and proliferation of U251 glioblastoma cells ( Figure 3B ).

[0673] in conclusion

[0674] Thus, provided herein are methods for treating cancer (e.g., gastric cancer or glioblastoma) or for promoting motor neuron survival and motor neuron axon growth by contacting human cells (e.g., cancer or neuronal cells) with a SSO that results in the inclusion of a pseudoexon into LINGO2 mRNA.

[0675] Example 6-TAF2

[0676] Purpose

[0677] The TAF2 gene expresses Tata box binding protein-associated factor 2, which is a subunit of the transcription factor IID complex and is involved in binding to promoter sequences to initiate transcription (Martinez et al., 1998). TAF2 exhibits copy number gain or mRNA overexpression in 73% of high-grade serous ovarian cancer (HGSC) (Ribeiro et al., 2014) and is important in cancer.

[0678] Materials and Methods

[0679] We use the analysis pipeline ( Figure 2 ) to analyze publicly available RNA-seq data. NCI-H358 lung cancer cells were grown in RPMI and transfected with 20 nM SSO using Lipofectamine. After 24 hours, cells were harvested and RNA was purified. RT-PCR was performed and the resulting products were visualized on a 2% agarose gel. WST-1 detection was performed 48 hours after transfection. For the Incucyte experiment, NCI-H358 lung cancer cells were grown in 96-well plates transfected with 10 nM SSO and incubated in the Incucyte instrument, and images were taken every 4 hours.

[0680] result:

[0681] The inclusion of the chr8:119779073-119779146(-)TAF2 pseudoexon will introduce 73 bp between exons 17 and 18 of the mRNA, resulting in a frameshifted reading frame with a premature stop codon in exon 18. TAF2 mRNA transcripts containing this pseudoexon are targets for nonsense-mediated mRNA decay (NMD), and the increased pseudoexon inclusion induced by SSO treatment will therefore lead to a decrease in TAF2 mRNA expression. In addition, if translated, transcripts containing the pseudoexon will result in the production of severely truncated proteins without normal TAF2 function.

[0682] By using an SSO targeting the TAF2 optimal site region according to SEQ ID NO:23 (the specific target sequence is underlined in SEQ ID NO:23 in Table 1), we demonstrated a high level of inclusion of the chr8:119779073-119779146(-)TAF2 pseudoexon in NCI-H358 lung cancer cells (Figure 4A). When NCI-H358 lung cancer cells were studied with this SSO, we observed a reduction in growth and proliferation by incucyte assay (Figure 4B) and WST-1 assay (Figure 4C).

[0683] in conclusion

[0684] Employing SSOs targeting the TAF2 pseudoexon resulted in increased pseudoexon inclusion and decreased cancer cell proliferation. Therefore, SSOs targeting the TAF2 pseudoexon may be candidates for future anticancer therapy.

[0685] Example 7 - HTT

[0686] Purpose

[0687] HTT encodes the huntingtin protein and is associated with the autosomal dominant neurodegenerative disorder Huntington's disease, which is caused by an unstable expansion of the CAG trinucleotide repeat sequence in the HTT gene, resulting in the translation of a cytotoxic mutant protein with an abnormal polyglutamine tract. Downregulation of HTT has been investigated as a potential strategy for treating Huntington's disease by reducing the levels of mutant huntingtin protein.

[0688] Inclusion of the chr4:3102605-3102748(+)HHT pseudoexon will introduce 143 bp between exons 3 and 4 of the mRNA, including an in-frame premature stop codon. HTT mRNA transcripts containing this pseudoexon are targets for nonsense-mediated decay (NMD), and increased pseudoexon inclusion induced by SSO treatment will lead to a decrease in HTT mRNA expression. Huntington's disease is an autosomal dominant disease caused by the expansion of a dominant negative trinucleotide repeat sequence in the HTT mRNA. Inclusion of PE will reduce the levels of the dominant negative mRNA and can therefore be used as a treatment.

[0689] Materials and Methods

[0690] We use the analysis pipeline ( Figure 2 ) to analyze publicly available RNA-seq data. HeLa cells were grown in RPMI and transfected with 20 nM SSO using Lipofectamine. After 24 hours, cells were harvested and RNA was purified. RT-PCR was performed and the resulting products were visualized on 2% agarose gel.

[0691] result

[0692] By using an SSO targeting the optimal site region according to SEQ ID NO:15 (the specific target sequence is underlined in SEQ ID NO:14 in Table 1), we demonstrated high-level inclusion of the HHT pseudoexon at chr4:3102605-3102748(+) in HeLa cells, which resulted in degradation of HTT mRNA by the NMD system (data not shown).

[0693] in conclusion

[0694] Employing an SSO targeting the HTT pseudoexon resulted in increased pseudoexon inclusion, which is suitable for downregulating a dominant negative mRNA that causes Huntington's disease.

[0695] Example 8 - Other related targets

[0696] The following additional optimal site sequences were identified using the criteria according to the invention (see, e.g., Example 2). Therefore, these targets are most likely functional targets for SSOs, allowing the incorporation of pseudoexons in mature mRNA.

[0697] Table 3: Related target genes

[0698]

[0699]

[0700]

[0701] Underlined SSO binding sequences that have been tested or preferred. Binding to the corresponding pre-mRNA. hg38 genomic coordinates follow the GFF / GTF format; 1-based start and end coordinates.

[0702] ROCK1:

[0703] ROCK1 encodes a Rho-associated serine / threonine kinase. The signaling pathway of ROCK1 has been implicated in the pathogenesis of metabolic diseases and several neurodegenerative disorders, such as Huntington's disease, Parkinson's disease, and Alzheimer's disease, and is a promising target for the treatment of neurodegenerative disorders by inhibiting its function (Koch et al., 2018). Inhibition of ROCK1 is an effective target for the treatment of chronic ophthalmic diseases (Moshifar et al., 2018). Hepatic ROCK1 is a proposed target for the treatment of nonalcoholic fatty liver disease and hepatocellular carcinoma (Huang et al., 2018; Wu et al., 2021).

[0704] Inclusion of the chr18:21022445-21022564(-)ROCK1 pseudoexon will introduce 120 bp into the mRNA between exons 11 and 12, including an in-frame premature stop codon. mRNA transcripts containing this pseudoexon are predicted to be targets for nonsense-mediated decay, and increased pseudoexon inclusion will lead to decreased gene expression.

[0705] The inclusion of chr18:21017021-21017098(-)ROCK1 pseudoexon will introduce 78 bp between exons 12 and 13 in the mRNA. In the translation of the protein, this will introduce 26 amino acids in the amino acid sequence. This will potentially reduce gene expression by disrupting protein function or altering normal protein function.

[0706] The optimal sites for ROCK1 SSO targeting are shown in Tables 3 and 6.

[0707] Koch JC,Tatenhorst L,Roser AE,Saal KA, L, Lingor P. ROCKinhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. 2018 Sep; 189:1-21. Moshirfar M, Parker L, Birdsong OC, Ronquillo YC, Hofstedt D, Shah TJ, Gomez AT, Hoopes PCS. Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature.Med Hypothesis DiscovInnov Ophthalmol.2018Fall;7(3):101-111.Huang H,Lee SH,Sousa-Lima I,Kim SS,Hwang WM,Dagon Y,Yang WM,Cho S,Kang MC,Seo JA,Shibata M,Cho H,Belew GD,BhinJ,Desai BN,Ryu MJ,Shong M,Li P,Meng H,Chung BH,Hwang D,Kim MS,Park KS,MacedoMP,White M,Jones J,Kim YB.Rho-kinase / AMPK axis regulates hepatic lipogenesis during overnutrition.J Clin Invest.2018Dec3;128(12):5335-5350.Wu H et al., (2021) Biochemical Pharmacology Volume 184, February 2021,114353.(https: / / doi.org / 10.1016 / j.bcp.2020.114353 )

[0708] OGA

[0709] O-GlcNAcylation of proteins is an important post-translational regulatory modification. This process is dynamic, and the protein O-GlcNAcase encoded by the OGA gene is responsible for removing the group again.

[0710] In animal models of Alzheimer's disease (AD), inhibitors of OGA blocked cognitive decline and reduced the number of amyloid plaques (Yuzwa, Shan et al., 2014), and reduced the amount of pathological Tau in the brain (Graham, Gray et al., 2014, Hastings, Wang et al., 2017). In addition, inhibition of OGA can reduce the cellular internalization of α-synuclein preformed fibrils and may become a strategy for the treatment of Parkinson's disease (PD) (Tavassoly, Yue et al., 2021).

[0711] The insertion of the chr10:101795374-101795480(-) and chr10:101795365-101795480(-) pseudoexons located in OGA intron 10 introduced a premature stop codon that targeted the resulting transcript for degradation by the NMD pathway. By functionally mimicking OGA repression, SSO-mediated OGA downregulation may be a promising approach for several neurological diseases including AD and PD.

[0712] The optimal sites targeted by OGA SSO are shown in Tables 3 and 6.

[0713] Graham, DL et al., 2 Neuropharmacology 79:307-313.

[0714] Hastings, NB et al., 2017. Mol Neurodegene 12(1):39.

[0715] Tavassoly, O. et al., 2021. FEBS J 288(2):452-470.

[0716] Yuzwa, SA et al., 2014. Mol Neurodegener 9:42.

[0717] TMEM97

[0718] Transmembrane protein 97 (TMEM97), also known as Sigma-2 receptor, plays an important role in cholesterol homeostasis. TMEM97 has been shown to be overexpressed in several cancers, and inhibition of its expression can inhibit the growth and metastasis of glioma cancer cells (Qiu, Sun et al., 2015). TMEM97 is also involved in the pathology of neurodegenerative diseases such as Alzheimer's disease, and its inhibition may be a potential therapy (Riad, Lengyel-Zhand et al., 2020). Inhibition of TMEM97 is also considered a potential therapy for Niemann-Pick type C disease (Ebrahimi-Fakhari, Wahlster et al., 2016).

[0719] SSO-mediated inclusion of the chr17:28320422-28320470(+) pseudoexon in intron 1 of TMEM97 introduces a premature stop codon that targets the resulting transcript for degradation by the NMD pathway, thus downregulating TMEM97 gene expression.

[0720] The optimal sites for TMEM97 SSO targeting are shown in Tables 3 and 6.

[0721] Ebrahimi-Fakhari, D. et al., 2016. Hum Mol Genet 25(16):3588-3599.

[0722] Qiu, G. et al., 2015. Tumour Biol 36(10):8231-8238.

[0723] Riad, A. et al., 2020. Mol Neurobiol 57(9):3803-3813.

[0724] TXNRD1

[0725] Thioredoxin reductase 1, encoded by TXNRD1, is associated with poor prognosis in patients with hepatocellular carcinoma (HCC) (Fu et al., 2017). In HCC tissues and cells, TXNRD1 is overexpressed and positively correlated with increased clinical stage and shortened survival (Fu et al., 2107). It has also been found to be mutated in a variety of cancers, including HCC (Jia et al., 2020). Therefore, it is a promising therapeutic target for target downregulation.

[0726] Transcripts that include a 158 nt long pseudoexon located within intron 4 of the reference transcript are degraded by the NMD system due to the introduction of a frameshift and the resulting premature stop codon. It may also result in the production of a severely truncated protein that lacks the active site amino acids necessary for reductase activity. Both scenarios lead to a complete loss of function of the gene product when transcripts contain the pseudoexon.

[0727] The optimal sites for TXNRD1 targeting are shown in Tables 3 and 6.

[0728] Fu B et al., Biomed Res Int. 2017; 2017:4698167. doi:10.1155 / 2017 / 4698167.

[0729] Jia Y et al., Mol Clin Oncol. 2020 Dec;13(6):83. doi:10.3892 / mco.2020.2153.

[0730] SLC7A11

[0731] The solute carrier SLC7A11 is a member of the cystine / glutamate transporter system Xc- and encodes xCT, which is overexpressed in many cancers and is a marker of poor prognosis (see Lin et al., 2020). In glioblastoma, this leads to increased glutamate secretion and neuronal death (Savaskan et al., 2008). Inhibition of xCT reduces neuronal death and edema and prolongs survival in rats with glioma (Savaskan et al., 2008). SLC7A11 upregulation also has an important cytoprotective effect in KRAS mutant cells by increasing intracellular antioxidant glutathione levels (Lim et al., 2019), and knockdown of SLC7A11 strongly impairs the growth of tumor xenografts (Lim et al., 2019). SLC7A11 is a candidate therapeutic target for KRAS-driven tumors (which are often highly treatment resistant) and many other cancers, including glioma. Although several xCT inhibitors exist, they are less specific than SSO-mediated SLC7A11 downregulation and may result in significantly more side effects when used in a clinical setting compared with SSO-based treatments.

[0732] The inclusion of a 56 nt pseudoexon located within intron 6 can lead to the introduction of a frameshift and a resulting premature stop codon, resulting in NMD-sensitive transcripts that may be downregulated or express truncated and nonfunctional proteins.

[0733] The optimal sites for SLC7A11 SSO targeting are shown in Tables 3 and 6.

[0734] Therefore, treatment with SSO to knock down SLC7A11 is a promising therapy for several cancers, with greater specificity and fewer side effects than current protein inhibitors.

[0735] Lin W et al., Am J Cancer Res. 2020 Oct 1; 10(10): 3106-3126.

[0736] Savaskan NE et al., Nat Med. 2008 Jun; 14(6): 629-32. doi: 10.1038 / nm1772.

[0737] Lim JKM et al., Mol Cell Oncol. 2019 Nov 10;7(1):1654814. doi:10.1080 / 23723556.2019.1654814.

[0738] Lim JKM et al., Proc Natl Acad Sci US A. 2019 May 7; 116(19): 9433-9442. doi: 10.1073 / pnas.1821323116.

[0739] cancer

[0740] PEs in the known oncogenes STAT5B (de Araujo, Erdogan et al., 2019), MCCC2 (Chen, Zhang et al., 2021), UBAP2L (Li, Wang et al., 2018), SMYD2 (Li, Zhou et al., 2018), YBX1 (Xu, Li et al., 2017), PTPN11 (Chan, Kalaitzidis et al., 2008), DIAPH3 (Rong, Gao et al., 2020), COPS3 (Zhang, Yan et al., 2018), SNX5 (Zhou, Huang et al., 2020), and ZYG11A (Wang, Sun et al., 2016) all result in the inclusion of an out-of-frame PE. Therefore, the inclusion of these PEs will lead to NMD-mediated degradation of oncogenic mRNAs or the production of non-functional oncoproteins, and are therefore suitable for treatment by activating optimal site-containing SSOs as cancer treatments.

[0741] Chan, G. et al., 2008. Cancer Metastasis Rev 27(2):179-192.

[0742] Chen et al., 2021. Cancer Cell Int 21(1):22.

[0743] de Araujo, ED, et al., 2019. Nat Commun 10(1):2517.

[0744] Li, LX et al., 2018. Cell Death Dis 9(3):326.

[0745] Li, Q. et al., 2018. Med Sci Monit 24:7109-7118.

[0746] Namour, F. et al., 2012. Drugs RD 12(3):141-163.

[0747] Rong, Y. et al., 2020. J Cell Mol Med. doi:10.1111 / jcmm.16196

[0748] Wang, X. et al., 2016. Oncotarget 7(7):8029-8042.

[0749] Xu, L. et al., 2018. J Exp Clin Cancer Res 37(1):135.

[0750] Zhou, Q. et al., 2020. Oncogene 39(10):2140-2155.

[0751] Example 9 - HIF1A

[0752] Purpose

[0753] Hypoxia-inducible factor (HIF) is a transcription factor that is activated when oxygen levels decrease or in response to other environmental changes. HIF-1α promotes tumor progression in cancer by promoting angiogenic signaling (formation of new blood vessels from already excited vessels, invasiveness of cells, migration and recruitment of immunosuppressive cells to the tumor environment) (Tatrai et al., 2014). Previous studies have shown that knocking down HIF-1α can reduce tumor mass and migration of cancer cells, and the activation of oncogenes is highly correlated with the risk of metastasis, making HIF-1α a possible target for anticancer therapy (Dai et al., 2011).

[0754] Materials and Methods

[0755] We use the analysis pipeline ( Figure 2) to analyze publicly available RNA-seq data. Panc-1 cells were grown in RPMI and transfected with 40nM SSO using Lipofectamine. After 24 hours, cells were harvested and RNA was purified. RT-PCR was performed and the resulting products were observed on a 2% agarose gel. In order to determine the best SSO targeting the optimal site region, we tested several SSOs using a 25nt long SSO that targets the optimal site region of +9 to +13 positions downstream of the PE 5'ss. This shows that the SSO targeted from +10 (SEQ ID NO: 128) is superior in mediating pseudoexon inclusion to HIF1A transcripts. For hypoxia experiments, transfected Panc-1 or U251 cells were first incubated under normoxic conditions for 48 hours and then moved to a hypoxic chamber for incubation for 24 hours. In order to measure cell proliferation, viability and cytotoxicity with the best +10SSO, cells were subjected to WST-1 detection under normoxic and hypoxic conditions. For protein extraction, cell lysates were snap frozen at -80°C to limit the time under normoxic conditions. Protein lysates were benzonase treated, denatured proteins were separated on 4-12% Nupage SDS-gels, and analyzed by western blotting using antibodies against HIF1α and β-actin as controls.

[0756] SSO:

[0757] All SSOs are 25 nt long phosphorothioate RNA oligonucleotides with 2'-O-methyl modifications on each sugar moiety (produced by LGC Biosearch Technologies). The SSOs were used to target different locations within the optimal site region of the gene (relative to the 5' splice site of the pseudoexon). Thus, the SSOs bind within the optimal site.

[0758] Table 4:

[0759] SEQ ID NO Gene SSO name SSO sequence 5'->3' 127 HIF1A SSO+9 guccuucauaaacuaagcuugaauu 128 HIF1A SSO+10 aguccuucauaaacuaagcuugaau 129 HIF1A SSO+11 caguccuucauaaacuaagcuugaa 130 HIF1A SSO+12 ucaguccuucauaaacuaagcuuga 131 HIF1A SSO+13 uucaguccuucauaaacuaagcuug

[0760] result:

[0761] Using the analysis pipeline ( Figure 2) Analyzing publicly available RNA-seq data, we identified a 34nt pseudoexon between exons 4 and 5 of HIF1A (chr14:61724198-61724230(+)). The pseudoexon causes a frameshift and introduces a stop codon (UAA) in exon 5. To determine the optimal SSO targeting the optimal site region, we tested several SSOs using a 25nt long SSO targeting the optimal site region from positions +9 to +13 downstream of the PE 5'ss. This showed that SSOs targeting from +10 were superior in mediating pseudoexon inclusion into HIF1A transcripts. Transfection of U251 glioblastoma cells with the +10 SSO resulted in up to 60% pseudoexon inclusion ( Figure 6 A). Under normoxic conditions, HIF-1α is degraded by hydroxylation, so to investigate the effect of SSO on protein levels, Panc-1 cells were placed in a hypoxic environment, and protein extraction showed that +10SSO effectively reduced the level of HIF1A protein ( Figure 6 B). WST-1 assay of U251 cells grown under hypoxic conditions had lower viability when treated with +10 SSO compared to when treated with control SSO ( Figure 6 C).

[0762] in conclusion

[0763] It can be observed that it is possible to optimize the binding site within the HIF1A binding region. The best performing SSO is "HIF1A+10" (SEQ ID NO: 128)

[0764] Example 10-TRPM7

[0765] Purpose

[0766] TRPM7 belongs to the protein superfamily transient receptor potential (TRP), which conducts transmembrane transport of different ions. TRP proteins work as sensors and transducers, and when activated, they cause the transmembrane flow of ions, regulating related pathways and various physiological responses (Liu et al., 2014). TRPM7 can be cleaved by caspases, splitting the kinase domain from the pores of the membrane. Studies have shown that TRPM7 is highly expressed in brain tissue, and dysregulation of this channel is associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease dementia, and Alzheimer's disease. It was found that TRPM7 plays a key role in neuronal death in ischemic conditions by mediating Ca2+ influx leading to calcium overload, resulting in oxidative stress, nitric oxide production, and cell death (Leng et al., 2015; Sun et al., 2009). TRPM7 knockdown inhibits delayed neuronal cell death, which is a characteristic of patients with Alzheimer's disease, Huntington's disease, Parkinson's disease, and stroke. This suggests that knocking down TRPM7 could be a new treatment for neuronal disorders. TRPM7 also plays an important role in several types of cancer, including glioblastoma multiforme (GBM), retinoblastoma, nasopharyngeal carcinoma, leukemia, gastric cancer, prostate cancer, pancreatic cancer, breast cancer, head and neck cancer, and it is overexpressed in pancreatic cancer and lung cancer cells. Finally, TRPM7 plays a role in diabetes, kidney disease, and inflammatory diseases.

[0767] Materials and Methods

[0768] We use the analysis pipeline ( Figure 2 ) to analyze publicly available RNA-seq data. HeLa cells and U251 cells were grown in RPMI and transfected with 20nM or 40nM SSO using Lipofectamine. After 24 hours, cells were harvested and RNA was purified. RT-PCR was performed and the resulting products were visualized on 2% agarose gels. For Incucyte experiments, U251 cells were grown in 96-well plates transfected with 20 and 40nM SSO and incubated in the Incucyte instrument with images taken every 4 hours. Small SSO steps were performed using a 25nt long SSO that targets the optimal site region at positions +9 to +13 downstream of the PE 5'ss.

[0769] SSO:

[0770] All SSOs are 25 nt long phosphorothioate RNA oligonucleotides with 2'-O-methyl modifications on each sugar moiety (produced by LGC Biosearch Technologies). The SSOs were used to target different locations within the optimal site region of the gene (relative to the 5' splice site of the pseudoexon). Thus, the SSOs bind within the optimal site (see Table 5).

[0771] Table 5:

[0772]

[0773] result:

[0774] Using the analysis pipeline ( Figure 2 ), we identified a 60nt pseudoexon (chr15:50588192-50588250(-)) located between exons 27 and 28 of TRPM7. The pseudoexon results in the introduction of 20 amino acids in the cleavage site region between the channel domain and the kinase domain of the TRMP7 protein. To determine the optimal SSO targeting the optimal site region, we tested several 25nt long SSOs that target the optimal site region from positions +9 to +13 downstream of the PE 5'ss. This suggests that SSOs targeting from +13 are superior in mediating the inclusion of the pseudoexon into TRPM7 transcripts. Transfection of HeLa cells or U251 glioblastoma cells with the optimal +13 targeting SSO resulted in high inclusion of the pseudoexon, which reduced cancer cell growth and proliferation ( Figure 5 C).

[0775] in conclusion

[0776] Normal expression of TRPM7 protein was most effectively reduced by using an SSO that binds from the +13 position and mediates high levels of pseudoexon inclusion.

[0777] References:

[0778] Tátrai E et al.,Oncotarget 2017,8:44498-44510.

[0779] Dai Y et al., International Journal of Radiation Oncology*Biology*Physics2011,81:521-528.

[0781] Liu M et al., Cell Signal 2014, 26: 2773-2781.

[0782] Leng TD et al., CNS Neurosci Ther 2015, 21: 252-261.

[0783] Sun HS et al., Nat Neurosci 2009, 12: 1300-1307.

[0784] Example 11 - Other related targets verified by experiments

[0785] The following optimal site sequences were identified in disease-related genes using the criteria according to the invention (see, e.g., Example 2) and demonstrated by functional assays to be targets for SSOs, allowing the incorporation of pseudoexons in mature mRNA.

[0786] Materials and Methods

[0787] We used public RNA sequencing data (Geuvadis, E-MTAB-2836, E-MTAB-513, GSE52946 and GSE124439) and mapped them with STAR after excising aptamer contamination and low-quality bases with bbduk. HeLa cells were seeded in 12-well plates and forward transfected with 20 or 40 nM of 2'-O-methyl SSO with a full thiophosphate backbone at 60% confluence using Lipofectamine RNAiMAX (invitrogen). The non-binding control SSO (5'GCUCAAUAUGCUACUGCCAUGCUUG3') (SEQ ID NO: 126) was used as a control. RNA was collected 48 hours later, and RNA was isolated using Trizol (Invitrogen) and chloroform, followed by isopropanol precipitation. Complementary DNA (cDNA) was synthesized from 500 ng RNA using a high-capacity cDNA kit (Applied Biosystems). Primers were designed to span at least one exon-exon junction of adjacent exons flanking the pseudoexon of interest. PCR was performed using TEMPase hot start DNA polymerase (ampliqon) and 1 μl cDNA per reaction. 0.5 pmol / μl of each primer was used. PCR products were separated on 2% Seakem LE (Lonza) TBE agarose gels at 80 V for 1 hour.

[0788] The optimal site region is located from +9 to +39 of the 5' splice site of the pseudoexon.

[0789] All SSOs are 25 nt long phosphorothioate RNA oligonucleotides with 2'-O-methyl modifications on each sugar moiety (produced by LGC Biosearch Technologies). The SSOs are used to target positions +11 to +35 within the optimal site region of the gene (relative to the 5' splice site of the pseudoexon). Therefore, the SSOs bind within the optimal site.

[0790] result

[0791] Using our double-joining method, we further identified 46 completely spliced ​​pseudo exons and tested SSOs in the optimal site region from +11 to +35 downstream of the selected pseudo exons identified in the targeted RNA sequencing data (Table 6). All of these 46 selected SSOs were able to increase pseudo exon inclusion in the mRNA transcripts of the targeted genes (Table 6 below).

[0792] Table 6: 46 pseudoexons that met all criteria were all activated by SSOs located in the optimal site region, which was annotated by its genomic sequence (DNA).

[0793] Table 6: Targets functionally validated as SSOs responding to targeting optimal site sequences.

[0794]

[0795]

[0796]

[0797] *Also included in Table 3.

[0798] Underlined SSO binding sequences detected. Binding to the corresponding pre-mRNA. hg38 genomic coordinates follow the GFF / GTF format; 1-based start and end coordinates.

[0799] In Table 6, the best sites of SEQ ID 141 and 142 correspond to the major allele (C) of rs17444202. The best sites of SEQ ID 158 and 159 correspond to the minor allele (T) of rs17444202.

[0800] Seq ID NOs: 160-180 are additional pseudoexons in genes, at least one of which has been activated by an SSO targeting the optimal site (genes listed in Table 1 and Table 6). Seq ID NOs: 181-201 in Table 7 are other optimal site sequences identified using the criteria according to the present invention (see, e.g., Example 2). Therefore, these targets are most likely functional targets for SSOs, allowing the incorporation of pseudoexons in mature mRNA.

[0801] Table 7: Related target pseudoexons.

[0802]

[0803]

[0804]

[0805] Underlined SSO binding sequences detected. Binding to the corresponding pre-mRNA. hg38 genomic coordinates follow the GFF / GTF format; 1-based start and end coordinates.

[0806] Table 8: SSOs targeting SMAD2 and LRRK2

[0807]

[0808] Example 12-RNF115

[0809] RNF115 (RING finger protein 115), previously known as breast cancer associated 2 (BCA2), is a RING finger E3 ubiquitin that mediates polyubiquitination of substrates. RNF115 leads to ubiquitination and proteasomal degradation of the tumor suppressor p21 in breast cancer (Wang et al., 2013). In lung cancer, RNF115 also functions as an oncogene by regulating the Wnt / β-catenin pathway via ubiquitination of adenomatous polyposis coli (APC), leading to increased proliferation (Wu et al., 2021).

[0810] RNF115 is associated with breast cancer. It is overexpressed in more than 50% of invasive breast cancers, and its upregulation is associated with estrogen receptor-positive (ER+) status and poor prognosis.

[0811] Therefore, inhibiting RNF115 activity will inhibit β-catenin and play a role in suppressing cancers such as lung and breast cancer.

[0812] Through in silico analysis and in vivo experiments, we aimed to investigate the presence of pseudoexons in the RNF115 gene, which might serve to downregulate the expression of this gene.

[0813] Materials and Methods

[0814] We used our new double ligation approach to identify fragments with fully spliced ​​pseudoexons in the publicly available RNA-seq data E-MTAB-2836, E-MTAB-513, GSE52946, and GSE124439 from the GEUVADIS project. HeLa cells, NCI-H23 lung cancer cells, and NCI-H23 lung cancer cells were seeded in 12-well plates and forward transfected with 5nM, 10nM, or 20nM SSO at 60% confluence using Lipofectamine RNAiMAX (invitrogen).

[0815] The SSO (targeting SEQ ID NO: 106; the specific target sequence is underlined in SEQ ID NO: 106 in Tables 3 and 6) is a 25 nt long phosphorothioate RNA oligonucleotide with a 2'-O-methyl modification on each sugar moiety (produced by LGCBiosearch Technologies). The SSO is complementary to positions +11 to +35 within the optimal site region of the RNF115 gene (relative to the 5' splice site of the pseudoexon). Thus, the SSO binds within the optimal site.

[0816] A non-binding SSO (5'GCUCAAUAUGCUACUGCCAUGCUUG3') (SEQ ID NO: 126) with similar modifications was used as a negative control. RNA was collected 48 hours later, and RNA was isolated using Trizol (Invitrogen) and chloroform, followed by isopropanol precipitation. Complementary DNA (cDNA) was synthesized from 500ng RNA using a high-capacity cDNA kit (Applied Biosystems). Primers were designed to span at least one exon-exon connection of adjacent exons flanking the pseudoexon of interest. PCR was performed using TEMPase hot-start DNA polymerase (ampliqon) and 1μl cDNA per reaction. Each primer used 0.5pmol / μl. PCR products were separated at 80V for 1 hour on a 2% Seakem LE (Lonza) TBE agarose gel. Proteins were collected for Western blotting 72 hours later, and denatured proteins were separated on a 4-12% NuPAGE SDS-gel. Western blot analysis was performed using antibodies against RNF115 (ab187642, Abcam), β-catenin (#9587, Cell Signaling Technology), β-actin (used as a control) (ab8229, Abcam).

[0817] To measure cell proliferation, viability, and cytotoxicity with optimal +11 SSO, NCI-H23 cells were reverse transfected with gradient concentrations of SSO and subjected to WST-1 assay (Roche) 48 h after transfection.

[0818] result

[0819] Using our double-ligation approach to detect fragments with fully spliced ​​pseudo-exons, we identified a pseudo-exon in intron 3 of the RNF115 gene.

[0820] The inclusion of the chr1:145784178-145784251RNF115 pseudoexon will introduce 74 bp between exons 3 and 4 of the mRNA. This will lead to a reading frame shift and a resulting premature stop codon, leading to degradation through the NMD system. It will also lead to the production of a severely truncated protein (only 84 amino acids) that lacks functional domains. This truncated protein can function as a decoy by binding substrates and inhibiting polyubiquitination, and play a role in suppressing cancer (Tables 3 and 6).

[0821] Transfection of NCI-H23 cancer cells with an SSO (SEQ ID NO: 106) complementary to positions +11 to +35 downstream of the 5' splice site resulted in up to 90% or more of the pseudoexon being included ( Fig. 7A ).

[0822] Treatment via SSO-mediated downregulation inhibited the growth of NCI-H23 cancer cells as shown by WST-1 assay ( Figure 7B ). In addition, as shown by Western blot, RNF115 protein levels were severely reduced after treatment of NCI-H23 lung cancer cells ( Figure 7C As shown by Western blotting, reduced levels of functional RNF115 resulted in decreased levels of β-catenin ( Figure 7C ).

[0823] in conclusion

[0824] Using specific SSOs to increase the inclusion of a pseudoexon that disrupts the function of the normal gene product reduced normal expression of the RNF115 gene product by at least 90%. This reduced beta-actin expression and lung cancer cell growth, suggesting that SSO-based activation of the RNF115 pseudoexon plays a cancer-suppressing role.

[0825] Similarly, the inclusion of the chr1:145794075-145794196RNF115 pseudoexon will introduce 122 bp between exons 1 and 2 of the mRNA. This will result in a reading frame shift and a resulting premature stop codon, leading to degradation through the NMD system. It will also result in the production of a severely truncated protein that lacks functional domains. This truncated protein can act as a decoy by binding substrates and inhibiting polyubiquitination, and play a role in suppressing cancer (Table 7).

[0826] Similarly, the inclusion of the chr1:145784114-145784251RNF115 pseudoexon will introduce 138 bp between exons 3 and 4 of the mRNA. This will result in a premature stop codon only 12 codons downstream of glutamate 73, leading to degradation through the NMD system. It will also result in the production of a severely truncated protein (only 84 amino acids) that lacks functional domains. This truncated protein can act as a decoy by binding substrates and inhibiting polyubiquitination, and play a role in suppressing cancer (Table 7).

[0827] Similarly, the inclusion of the chr1:145780774-145780881RNF115 pseudoexon will introduce 108 bp between exons 3 and 4 of the mRNA. This will result in a premature stop codon only 24 codons downstream of glutamate 73, leading to degradation through the NMD system. It will also result in the production of a severely truncated protein (only 96 amino acids) that lacks functional domains. This truncated protein can act as a decoy by binding substrates and inhibiting polyubiquitination, and play a role in suppressing cancer (Table 7).

[0828] Similarly, the inclusion of the chr1:145759390-145759535RNF115 pseudoexon will introduce 146 bp between exons 4 and 5 of the mRNA. This will result in a frameshift after glycine 143 and a premature stop codon 94 downstream of the resulting codon, leading to degradation by the NMD system. It will also result in the production of a severely truncated protein (226 amino acids) that lacks functional domains. This truncated protein can act as a decoy by binding substrates and inhibiting polyubiquitination, and play a role in suppressing cancer (Table 7).

[0829] Wang Z, Nie Z, Chen W, Zhou Z, Kong Q, Seth AK et al., (2013) RNF115 / BCA2 E3ubiquitin ligase promotes breast cancer cell proliferation through targetingp21Waf1 / Cip1 for ubiquitin-mediated degradation.Neoplasia.15(9):1028–35.

[0830] Wu XT,Wang YH,Cai XY,Dong Y,Cui Q,Zhou YN,Yang XW,Lu WF,Zhang M.(2021)RNF115 promotes lung adenocarcinoma through Wnt / β-catenin pathwayactivation by mediating APC ubiquitination.Cancer Metab.9(1):7.

[0831] Example 13 - LRRK2

[0832] Purpose

[0833] Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons that affect motor control. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are common risk factors associated with Parkinson's disease (Alessi & Sammler, 2018). Dominantly inherited and sporadic pathogenic mutations in LRRK2 lead to overactivation of the LRRK2 kinase, and downregulating LRRK2 gene expression is a potential therapeutic strategy.

[0834] Materials and Methods

[0835] We use the analysis pipeline ( Figure 2) were used to identify fragments with fully spliced ​​pseudoexons in publicly available RNA-seq data. HeLa and U251 cells were reverse transfected with 20 nM SSO (targeting SEQ ID NO: 141 and SEQ ID NO: 142; specific target sequences are underlined in SEQ ID NO: 141 and SEQ ID NO: 142 in Table 6) using Lipofectamine RNAiMAX (invitrogen). Non-targeting SSO (5'-GCUCAAUAUGCUACUGCCAUGCUUG-3') (SEQ ID NO: 126) was used as a negative control. Cells were harvested 48 hours later using Trizol (Invitrogen) and RNA was extracted using chloroform and isopropanol. Complementary DNA (cDNA) was synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosystems) and PCR was performed using primers in LRRK2 exons 47 and 48 using TEMPase hot start DNA polymerase (Ampliqon). PCR products were separated on 1.5% SeaKem LE (Lonza) TBE agarose gel.

[0836] result

[0837] Using our analysis pipeline ( Figure 2 ), we identified two LRRK2 pseudoexons that can be activated by SSOs targeting optimal sites. The two pseudoexons: chr12:40362438-40362491(+) and chr12:40362410-40362491(+) are located within intron 47 and have the same 5' splice site. Transfection of HeLa and U251 cells with an SSO complementary to positions +11 to +35 downstream of the 5' splice site (SEQ ID NO:215) resulted in increased inclusion of the two pseudoexons between exons 47 and 48 in LRRK2 mRNA transcripts (Figure 9). The chr12:40362438-40362491(+) LRRK2 pseudoexon is 54nt long and the pseudoexon inclusion introduces 18 amino acids into the WD40 domain of the translated LRRK2 protein. chr12:40362410-40362491(+)LRRK2 pseudoexon is 82 nt long and contains an insertion that will cause a frameshift and a premature stop codon and targets the transcript for degradation through nonsense-mediated mRNA decay.

[0838] Surprisingly, it was found that the best site sequence identified had a SNP, namely rs17444202. Therefore, we used SSOs targeting SEQ ID NOs: 141 and 142 (corresponding to the major allele (C) of rs17444202), or SSOs targeting SEQ ID 158 and 159 (corresponding to the minor allele (T) of rs17444202) (see Table 6 in Example 11). In addition, we used SSOs with additional mismatches to achieve preferential targeting of the major or minor allele. All SSOs induced chr12: 40362438-40362491 (+) LRRK2 pseudo exon inclusion and chr12: 40362410-40362491 (+) LRRK2 pseudo exon inclusion (results not shown). The sequences of the SSOs used are listed in Table 8 of Example 11, as SEQ ID NOs: 208-216.

[0839] in conclusion

[0840] By using specific SSOs targeting optimal sites to induce pseudoexon inclusions, thereby reducing the expression and activity of the normal LRRK2 gene product, both normal and overactivated functions of LRRK2 will be reduced. Pseudoexon inclusions that introduce amino acids into the translated sequence will potentially reduce gene expression by disrupting protein function or altering normal protein function. Pseudoexon inclusions that cause frameshifts and insert premature stop codons will reduce gene expression by degradation of the transcript or translation of truncated and nonfunctional proteins.

[0841] Without being bound by theory, by screening the SNP status of the subject prior to selecting an SSO and initiating treatment, it is possible to perform allele-specific targeting (or at least allele-preferred targeting) by identifying SNPs in the optimal locus region.

[0842] Reference: Alessi, DR & Sammler E (2018) Science, 360(6384): 36-37. DOI: 10.1126 / science.aar5683

[0843] Example 14- LRP6

[0844] LRP6 (LDL receptor-related protein 6) is a member of the low-density lipoprotein (LDL) receptor gene family. LRP6 functions as a receptor and co-receptor for Wnt in the Wnt / β-catenin signaling cascade and plays a role in the regulation of cell differentiation, proliferation, and migration. It is also involved in glucose and lipid metabolism signaling. Inhibition of LRP6 could be a therapeutic option for cancers such as breast, liver, and colorectal cancers, as well as metabolic and neurodegenerative diseases (reviewed by Jeong and Jho 2021).

[0845] The inclusion of the chr12:12149294-12149360(-)LRP6 pseudoexon will introduce 67bp between exons 13 and 14 of the mRNA. This will lead to a reading frame shift and a resulting premature stop codon, leading to degradation via the NMD system. It will also lead to the production of a severely truncated protein (only 1006 amino acids) that lacks the transmembrane and cytosolic domains. This truncated protein can function as a decoy receptor for Wnt proteins, thereby inhibiting Wnt signaling and playing a role in suppressing cancer and other diseases. (Table 6 – Functional Validation)

[0846] Similarly, the inclusion of the chr12:12184211-12184244(-)LRP6 pseudoexon will introduce 34 bp between exons 4 and 5 of the mRNA. This will result in a frameshift and a resulting premature stop codon, leading to degradation through the NMD system. It will also result in the production of a severely truncated protein that lacks the transmembrane and cytosolic domains. This truncated protein can function as a decoy receptor for Wnt proteins, thereby inhibiting Wnt signaling and playing a role in suppressing cancer and other diseases (Table 7).

[0847] Similarly, the inclusion of the chr12:12212260-12212305(-)LRP6 pseudoexon will introduce 46 bp between exons 1 and 2 of the mRNA. This will result in a reading frame shift and a resulting premature stop codon, leading to degradation through the NMD system. It will also result in the production of a severely truncated protein that lacks the transmembrane and cytosolic domains. This truncated protein can function as a decoy receptor for Wnt proteins, thereby inhibiting Wnt signaling and playing a role in suppressing cancer and other diseases (Table 7).

[0848] Similarly, the inclusion of the chr12:12197784-12197878(-)LRP6 pseudoexon will introduce 95 bp between exons 3 and 4 of the mRNA. This will result in a frameshift and a resulting premature stop codon, leading to degradation through the NMD system. It will also result in the production of a severely truncated protein that lacks the transmembrane and cytosolic domains. This truncated protein can function as a decoy receptor for Wnt proteins, thereby inhibiting Wnt signaling and playing a role in suppressing cancer and other diseases (Table 7).

[0849] Example 15-LRRK2-SNP

[0850] Purpose

[0851] Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons that affect motor control. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are common risk factors associated with Parkinson's disease (Alessi & Sammler, 2018). Dominantly inherited and sporadic pathogenic mutations in LRRK2 lead to overactivation of the LRRK2 kinase, and downregulating LRRK2 gene expression is a potential therapeutic strategy. Allele-specific targeting is particularly promising for downregulating overactivated disease alleles with minimal or no effect on the wild-type allele.

[0852] Materials and Methods

[0853] We used RNA-seq analysis to identify fragments with fully included pseudoexons in both patent and publicly available RNA-seq data, and we used the dbSNP database (https: / / www.ncbi.nlm.nih.gov / SNP) to identify SNPs that enhance 3' or 5' splice sites (increase MaxEnt score). Such SNPs can make otherwise non-responsive pseudoexons functional targets for SSO therapy and allow inclusion of a given pseudoexon in mature mRNA or increase inclusion of a given pseudoexon.

[0854] A549 cells were reversely transfected with 30 nM SSO (5'-CAGACUACCAGACAUCUGACUAGAA-3') (SEQ ID NO:333) (targeting SEQ ID NO:217; the specific target sequence is underlined in SEQ ID NO:217 in Table 9) and LX-2 cells were forward transfected using Lipofectamine RNAiMAX (invitrogen). Non-targeting SSO (5'-GCUCAAUAUGCUACUGCCAUGCUUG-3') (SEQ ID NO:126) was used as a negative control. A549 cells were harvested 48 hours after transfection using Trizol (Invitrogen) and LX-2 cells were harvested 24 hours after transfection. RNA was extracted using chloroform and isopropanol, complementary DNA (cDNA) was synthesized using a high capacity cDNA reverse transcription kit (Applied Biosystems), and PCR was performed using primers in LRRK2 exons 37 and 38-39 using TEMPase hot start DNA polymerase (Ampliqon). PCR products were separated on 1.5% SeaKem LE (Lonza) TBE agarose gel.

[0855] result

[0856] We identified a pseudoexon in intron 37 of the LRRK2 gene; chr12:40322690-40322887(+). The common SNP: rs10878372A / G (frequency: A=0.77 / G=0.23, 1000 Genomes European population) increases the strength of the pseudoexon 5' splice site, which changes the MaxEnt score of -4.26 for the "A allele" to 4.84 for the "G allele". This pseudoexon can be activated by SSO, which only targets the best site region (G allele) in the gene allele with the identified SNP. This allows G allele-specific pseudoexon activation in heterozygotes (=35% of the 1000 Genomes European population) and pseudoexon activation of both alleles in individuals homozygous for the G allele, while SSO does not activate the pseudoexon in individuals homozygous for the A allele.

[0857] Transfection of A549 and LX-2 cells with an SSO complementary to positions +11 to +35 downstream of the 5' splice site (SEQ ID NO: 217) resulted in increased inclusion of the LRRK2 pseudoexon in LX-2 cells heterozygous for the rs10878372A / G SNP, but did not affect inclusion of the pseudoexon in A549 cells homozygous for the A allele (compare Fig. 10A and 10B). Inclusion of the LRRK2 pseudoexon would introduce 198 nt between exons 37 and 38 of the mature mRNA, including multiple in-frame premature translation stop codons.

[0858] in conclusion

[0859] The activity and function of LRRK2 will be reduced by using SSOs targeting the optimal site region to induce pseudo-exon inclusion and thereby reduce the expression of LRRK2 gene alleles that have an identified SNP (G) for allele-specific targeting. Pseudo-exon inclusion that introduces an in-frame premature stop codon will reduce gene expression through degradation of the transcript or translation of a truncated and non-functional protein.

[0860] By identifying SNPs that reinforce the 3' or 5' splice site of the pseudoexon, the pseudoexon becomes a functional target for SSO therapy to induce pseudoexon inclusion, making it possible to perform allele-specific targeting (or at least allele-preferred targeting) by screening subjects carrying a specific SNP and a dominant pathogenic mutation on the same allele before starting treatment.

[0861] Reference: Alessi, DR & Sammler E (2018) Science, 360(6384): 36-37. DOI: 10.1126 / science.aar5683

[0862] Example 16

[0863] Purpose

[0864] In many autosomal dominant diseases, allele-specific downregulation of expression from only the pathogenic (mutant) allele is preferred because the mutant allele produces a protein with a dominant negative effect that interferes with the normal protein produced by the wild-type allele. Similarly, in diseases caused by gene duplications, where the disease pathology is due to gene dosage sensitivity, allele-specific downregulation of only one allele is preferred. Activation of spurious exon splicing that results in the introduction of premature stop codons into the transcripts of mutant or overexpressed alleles will reduce gene expression by either degrading mutant transcripts or translating truncated and non-functional proteins.

[0865] SNPs located at the 23-mer 3' splice site (-20 to +3 nt of the intron-exon boundary) or the 9-mer 5' splice site (-3 to +6 nt of the exon-intron boundary) affect the strength of a given splice site (change the MaxEnt score). This can be used for allele-specific pseudoexon activation, because such high MaxEnt score SNP variants can make an otherwise non-responsive pseudoexon a functional target for SSO treatment, thereby allowing allele-specific inclusion or increased inclusion of a given pseudoexon in the mature mRNA transcript. The principle of the present invention is shown in Figure 11.

[0866] Therefore, allele-specific targeting (or at least allele-preferred targeting) can be performed by screening subjects carrying specific high MaxEnt scoring SNP variants before starting treatment with an SSO that binds to the optimal site.

[0867] Materials and Methods

[0868] We used RNA-seq analysis to identify fragments with completely included pseudo exons in patent and publicly available RNA-seq data, and we used the dbSNP database (https: / / www.ncbi.nlm.nih.gov / SNP) to identify SNPs that strengthen 3' or 5' splice sites (increase MaxEnt score). As shown in Example 15, such high MaxEnt score SNP variants make the otherwise non-responsive pseudo exons functional targets for SSO treatment and allow inclusion of a given pseudo exon in mature mRNA or increase the inclusion of a given pseudo exon.

[0869] result

[0870] We have identified the following additional examples of target pseudoexons where allele-specific activation of SSOs binding in the optimal site region is determined by SNP variants in the splice site sequence (Table 9). Table 9: Target pseudoexons where allele-specific activation is determined by SNP variants in the splice site sequence.

[0871]

[0872]

[0873]

[0874]

[0875]

[0876]

[0877]

[0878] SNP ID. Refers to the SNP number in dbSNP (https: / / www.ncbi.nlm.nih.gov / snp / ).

[0879] Underlined SSO binding sequences tested. Binding to the corresponding pre-mRNA. hg38 genomic coordinates follow the GFF / GTF format; 1-based start and end coordinates.

[0880] In some cases, gene names are extended with sequence codes.

[0881] Table 10: SSOs capable of allele-specific activation of pseudoexons.

[0882]

[0883]

[0884]

[0885]

[0886] Selected Instance

[0887] LMN1B:

[0888] Lamin B1 is encoded by the LMNB1 gene. Overexpression of lamin B1 leads to progressive central nervous system demyelination, resulting in autosomal dominant adult-onset demyelinating leukodystrophy (ADLD) (Giorgio et al., 2015; Giorgio et al., 2019). ADLD is an inherited, progressive, and fatal disorder affecting the myelin sheath in the central nervous system (CNS). Allele-specific downregulation of one LMNB1 allele is a suitable and promising therapeutic option for ADLD (Giorgio et al., 2019).

[0889] In addition, LMNB1 expression is increased in cancer and correlates with cancer stage and patient prognosis. Downregulation of LMNB1 reduces cancer cell proliferation and migration as well as tumor growth. Therefore, LMNB1 downregulation is also a promising strategy for cancer treatment (Li et al., 2022).

[0890] We identified a pseudoexon in intron 1 of the LMNB1 gene; chr5:126804263-126804357(+). The strength of the pseudoexon 5' splice site was determined by a common SNP; rs30485331- / insTT (frequency:-=0.80 / insTT=0.2, 1000Genomes European population). The insTT variant changed the MaxEnt score of 7.10 for the-allele to -20.37 for the insTT allele (low MaxEnt score SNP variant). This pseudoexon can be activated by SSO that targets only the best site region in the gene allele that does not have the identified SNP (insTT allele). This allows allele-specific pseudoexon activation in heterozygotes (=32% of the 1000Genomes European population) and pseudoexon activation of both alleles in individuals homozygous for the -- allele (high MaxEnt scoring SNP variant), while SSO does not activate pseudoexons in individuals homozygous for the insTT allele (low MaxEnt scoring SNP variant).

[0891] The inclusion of the chr5:126804263-126804357(+)LMNB1 pseudoexon will introduce 95 bp between exon 1 and exon 2 of the mRNA. This will introduce an in-frame premature stop codon in the mRNA transcript. Therefore, LMNB1 mRNA transcripts containing this pseudoexon are predicted to be targets for nonsense-mediated attenuation, and increased pseudoexon inclusion will lead to a decrease in LMNB1 gene expression.

[0892] The optimal sites for LMNB1 SSO targeting are shown in Table 9.

[0893] References:

[0894] Giorgio E, Robyr D, Spielmann M, Ferrero E, Di Gregorio E, Imperiale D, Vaula G, Stamoulis G, Santoni F, Atzori C, Gasparini L, Ferrera D, Canale C, Guipponi M, Pennacchio LA, Antonarakis SE, Brussino A, Brusco AA large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path toautosomal dominant adult-onset demyelinating leukodystrophy(ADLD). Hum MolGenet. 2015 Jun 1;24(11):3143-54. doi:10.1093 / hmg / ddv065. Epub 2015 Feb 20. PMID:25701871;PMCID:PMC4424952.

[0895] Giorgio E, Lorenzati M, Rivetti di Val Cervo P, Brussino A, Cernigoj M, Della Sala E, Bartoletti Stella A, Ferrero M, Caiazzo M, Capellari S, Cortelli P, Conti L, Cattaneo E, Buffo A, Brusco A. Allele-specific silencing as treatment for gene duplication disorders: proof-of-principle in autosomal dominant leukodystrophy. Brain. 2019 Jul 1;142(7):1905-1920. doi:10.1093 / brain / awz139. PMID:31143934.

[0896] Li J,Sun Z,Cui Y,Qin L,Wu F,Li Y,Du N,Li X.Knockdown of LMNB1Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage andCell Senescence.Front Oncol.2022May 31;12:913740.doi:10.3389 / fonc.2022.913740.PMID:35712471;PMCID:PMC9194513.

[0897] ATXN2:

[0898] Ataxin-2 is encoded by the ATXN2 gene. Spinocerebellar ataxia 2 (SCA2) is an autosomal dominant lethal disease caused by expansion of one ATXN2 allele to more than 32 CAG repeats (Laffita-Mesa et al., 2021). Alleles with moderate (≥29 CAG / CAA repeats) expansions in ATXN2 increase the risk of many other neurological diseases. Reducing ATXN2 expression in mice with amyotrophic lateral sclerosis (ALS) prolongs their survival, suggesting that reduced expression of the ATXN2 disease allele may be therapeutically relevant for both ALS and SCA2 (Laffita-Mesa et al., 2021).

[0899] Therefore, allele-specific downregulation of an ATXN2 disease-associated allele would be a suitable therapeutic option for SCA2, ALS, and other neurodegenerative diseases.

[0900] We identified a pseudoexon in intron 14 of the ATXN2 gene; chr12:111505733-111505834(-). The strength of the pseudoexon 5' splice site was determined by a common SNP; rs10849953A / G (frequency: A=0.58 / G=0.42, 1000Genomes Japanese population). The G variant changed the MaxEnt score of the A allele from -1.34 to 6.84 for the G allele (high MaxEnt score SNP variant). Therefore, this pseudoexon can be activated by SSO that targets only the optimal site region (G allele) in the gene allele with the identified SNP. This allows allele-specific pseudoexon activation in heterozygotes (=49% of the 1000 Genomes Japanese population) and pseudoexon activation of both alleles in individuals homozygous for the G allele, while SSO does not activate pseudoexons in individuals homozygous for the A allele (low MaxEnt scoring SNP variant).

[0901] The inclusion of the chr12:111505733-111505834(-)ATXN2 pseudoexon will introduce 102 bp between exon 14 and exon 15 of the mRNA. This will introduce an in-frame premature stop codon in the mRNA transcript. Therefore, the ATXN2 mRNA transcript containing this pseudoexon is predicted to be a target for nonsense-mediated attenuation, and increased pseudoexon inclusion will lead to a decrease in ATXN2 gene expression.

[0902] The optimal sites for ATXN2 SSO targeting are shown in Table 9.

[0903] References: Laffita-Mesa JM, Paucar M, Svenningsson P. Ataxin-2gene: a powerful modulator of neurological disorders. Curr Opin Neurol.2021Aug1;34(4):578-588.doi:10.1097 / WCO.0000000000000959.PMID:34010218;PMCID:PMC8279897.

Claims

1. A composition comprising a splice switching oligonucleotide (SSO) for use as a medicament, the composition comprising: - A SSO that is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of: o a nucleic acid according to any one of SEQ ID NOs: 217-294; o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 217-294; or o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 217-294; or - An SSO selected from the group consisting of: o a nucleic acid according to any one of SEQ ID NOs: 295-367; or o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NOs: 295-367; or o a nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 295-367; wherein the SSO is complementary or substantially complementary to a target pre-mRNA, the target pre-mRNA comprising: - Functionally disabling pseudoexons, including: o 3' splice site at the 5' end; and o 5' splice site at the 3' end; The SSO is complementary or substantially complementary to the target pre-RNA in the region +9 to +39 downstream of the 5' splice site of the pseudo exon.

2. The composition of claim 1, wherein the SSO is complementary or substantially complementary to a region within a nucleic acid selected from the group consisting of: o a nucleic acid according to any one of SEQ ID NO: 217; o a nucleic acid comprising 1 or 2 or 3 substitutions compared to any one of SEQ ID NO: 217; or o A nucleic acid sequence having at least 90% sequence identity to any one of SEQ ID NO:

217.

3. A composition according to claim 1 or 2, wherein the composition is used to treat a human subject suffering from a disease or condition characterized by increased expression or altered function of a functional protein that causes or affects the condition, or in which decreased expression of a functional gene product is therapeutically beneficial.

4. The composition according to any one of the preceding claims, wherein the SSO comprises a sequence that is substantially complementary to a polynucleotide in a pre-mRNA, comprising at most 3 mismatches, such as at most 2 mismatches or such as at most 1 mismatch.

5. A composition according to any one of the preceding claims, wherein the length of the SSO is in the range of 9-100 nucleotides, such as 9-50 nucleotides, preferably in the range of 9-40 nucleotides, more preferably in the range of 9-31 nucleotides or 9-25 nucleotides.

6. A composition according to any one of the preceding claims, wherein the SSO comprises a sequence that is complementary or substantially complementary to a polynucleotide in a pre-mRNA as defined above, wherein the length of the sequence is in the range of 9-31 nucleotides, such as 9-20 nucleotides, preferably the sequence is complementary in the range of 9-31 nucleotides, such as 9-20, or such as 20-31 nucleotides, such as 25-31 nucleotides.

7. The composition according to any one of the preceding claims, wherein the SSO comprises one or more artificial nucleotides, such as sugar-modified nucleotides.

8. The composition of any one of the preceding claims, wherein the oligonucleotide does not mediate RNase H-mediated mRNA degradation.

9. The composition of claim 7 or 8, wherein at least one modified sugar moiety is a 2'-substituted sugar moiety.

10. The composition of claim 9, wherein the 2'-substituted sugar moiety has a 2'-substitution selected from the group consisting of 2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), and 2'-O-methoxyethyl (2'-MOE).

11. A composition according to any one of the preceding claims for use in treating or ameliorating a disease selected from the group consisting of cancer, inflammatory diseases, neurodegenerative or neurological diseases, metabolic conditions, chronic liver diseases and inherited retinal dystrophy (IRD).

12. The composition of any of the preceding claims, wherein the composition is administered to a subject who is heterozygous for a sequence variation (SNP) in the pre-mRNA targeted by the SSO, whereby the SSO promotes inclusion of a functionally disabling pseudoexon in the pathogenic allele to a greater extent than in other alleles; or Wherein the composition is administered to a subject that is homozygous for a SNP variation (SNP) in the pre-mRNA targeted by the SSO.

13. The composition according to any of the preceding claims, wherein the subject is heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site, preferably the 5' splice site, of the functionally disabling pseudoexon.

14. The composition according to claim 12 or 13, wherein the SNP is a point mutation, an insertion of 1-20 nucleotides at the SNP position, or a deletion of 1-20 nucleotides at the SNP position.

15. The composition of claim 14, wherein the SNP is located at the 3' splice site or the 5' splice site.

16. The composition of any one of claims 12 to 15, wherein when contacted with the SSO, heterozygosity in the causative gene increases the inclusion of a pseudoexon of one allele in the mature mRNA to a greater extent than the corresponding gene on the other allele.

17. A composition according to any one of claims 12 to 16, wherein heterozygosity in the pathogenic gene increases the MaxEnt score of the splice site of the pseudoexon in the pathogenic gene compared to the corresponding (normally functioning) gene on the other allele.

18. A composition according to any one of claims 12 to 17, wherein heterozygosity in the pathogenic gene results in a higher MaxEnt score for the splice site of the pseudoexon in the pathogenic gene compared to the corresponding (normally functioning) gene on the other allele.

19. A composition according to any one of claims 12 to 18, wherein the splice site of the pseudoexon in the pathogenic gene allele has a higher MaxEnt score than the corresponding splice site of the (normally functioning) gene on the other allele.

20. The composition of any one of claims 12 to 19, wherein the subject has a SNP in a causative allele selected from the group of SNP IDs according to Table 9.

21. The composition of any one of claims 12 to 20, wherein the subject has a SNP in a causative allele selected from the group of SNPs according to Table 9, and the SSO targets the corresponding optimal site sequence according to Table 9.

22. The composition of any one of the preceding claims, wherein the pre-mRNA encodes LRRK2.

23. The composition of any of the preceding claims, wherein the pre-mRNA encodes LRRK2 and the subject has a high MaxEnt score "G allele" of SNP rs10878372 in the pathogenic LRRK2 allele.

24. The composition of any of the preceding claims, wherein the pre-mRNA encodes LRRK2 and the subject is heterozygous for a pathogenic mutation in LRRK2.

25. A method for identifying subjects who may meet criteria for allele-specific SSO-based pseudoexon inclusion therapy for a dysfunctional gene or a pathogenic gene, the method comprising - determining the presence or absence of heterozygosity in a pseudoexon of a dysfunctional gene or a disease-causing gene in a biological sample from the subject; wherein if the subject is heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site, preferably in the 5' splice site, of the functionally disabling pseudoexon, then the subject may meet the criteria for allele-specific SSO-based pseudoexon inclusion treatment; or wherein if the subject is not heterozygous for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site of the functionally disabling pseudoexon, the subject may not meet criteria for allele-specific SSO-based pseudoexon inclusion treatment; Wherein the SSO is complementary or substantially complementary to a target pre-mRNA of a dysfunctional gene or a disease-causing gene, the target pre-mRNA comprising: - Functionally disabling pseudoexons, including: o 3' splice site at the 5' end; and o 5' splice site at the 3' end.

26. The method of claim 25, wherein the pseudo-exon containing treatment based on the allele-specific SSO causes the SSO to hybridize with the pre-mRNA in vivo, and the pseudo-exon of the dysfunctional gene or pathogenic gene becomes part of the mature mRNA to a greater extent than the corresponding pre-mRNA not contacted with the SSO.

27. The method of claim 25 or 26, wherein the pseudo-exon containing treatment based on the allele-specific SSO causes the SSO to hybridize with the pre-mRNA in vivo, and the pseudo-exon in the allele having a dysfunctional gene or a pathogenic gene becomes part of the mature mRNA to a greater extent than the corresponding pre-mRNA not contacted with the SSO.

28. The method according to any one of claims 25 to 27, wherein when / if contacted with the SSO, heterozygosity for a sequence variation (SNP) in the 5' splice site and / or the 3' splice site of the pseudo-exon in the pre-mRNA targeted by the SSO will promote the pathogenic allele to include the functionally disabling pseudo-exon to a greater extent compared to other alleles.

29. The method according to any one of claims 25 to 28, wherein the heterozygosity of the sequence variation (SNP) is at the 5' splice site and / or the 3' splice site of the functionally disabling pseudoexon, preferably the 5' splice site.

30. The method according to any one of claims 25 to 29, wherein the heterozygosity of the sequence variation (SNP) in the pathogenic gene is a point mutation (SNP), an insertion of 1-20 nucleotides or a deletion of 1-20 nucleotides, preferably a point mutation.

31. The method of any one of claims 25 to 30, wherein when / if contacted with the SSO, heterozygosity for a sequence variation (SNP) in the causative gene increases inclusion of the pseudoexon to a greater extent than the corresponding (normally functioning) gene on the other allele.

32. A method according to any one of claims 25 to 31, wherein the heterozygosity of the sequence variation (SNP) in the pathogenic gene increases the MaxEnt score of the splice site compared to the corresponding splice site of the (normally functioning) gene on the other allele.

33. A method according to any one of claims 25 to 32, wherein the heterozygosity of the sequence variation (SNP) in the pathogenic gene results in a higher MaxEnt score for the splice site compared to the corresponding splice site in the (normally functioning) gene on the other allele.

34. A method according to any one of claims 25 to 33, wherein the heterozygosity of the sequence variation (SNP) in the pathogenic gene is in the splice site of the pseudoexon of the pathogenic gene, resulting in a higher MaxEnt score compared to the corresponding splice site of the (normally functioning) gene on the other allele.

35. The method of any one of claims 25 to 34, wherein the allele-specific SSO-based pseudoexon inclusion therapy comprises therapy with the SSO, when the SSO hybridizes in vivo to a pre-mRNA, that hybridizes in vivo to a greater extent to a pre-mRNA of an allele having the pathogenic allele than to an allele not having the pathogenic allele.

36. The method of any one of claims 25 to 35, wherein the SSO is complementary or substantially complementary to the target pre-RNA in the region +9 to +39 downstream of the 5' splice site of the pseudoexon.

37. The method according to any one of claims 25 to 36, wherein the target sequence of the SSO is located in a gene selected from the group consisting of LRRK2, LMN1B and ATXN2.

38. The method of any one of claims 25 to 37, wherein the subject has a SNP in a causative allele selected from the group of SNP IDs according to Table 9.

39. The method according to any one of claims 25 to 38, wherein the subject has a SNP in two alleles selected from the group of SNP IDs according to Table 9.

40. The method according to any one of claims 25 to 39, wherein the allelic status is determined by a method selected from the group consisting of: such as Sanger sequencing, next generation sequencing (NGS) and mutation-specific assays such as ARMS and Taq-man.

41. A method for identifying subjects who may meet criteria for SSO-based pseudoexon inclusion treatment of a dysfunctional gene or a pathogenic gene, the method comprising - determining the presence or absence of a SNP in a pseudoexon of a dysfunctional gene or a disease-causing gene in a biological sample from the subject, which enables SSO-based pseudoexon inclusion therapy; wherein if the subject has a sequence variation (SNP) at the 5' splice site and / or the 3' splice site, preferably the 5' splice site, of the functionally disabling pseudoexon, then the subject may meet the criteria for SSO-based pseudoexon inclusion treatment; or wherein if the subject does not have a sequence variation (SNP) at the 5' splice site and / or the 3' splice site of the functionally disabling pseudoexon, the subject may not meet the criteria for SSO-based pseudoexon inclusion treatment; o Wherein the SSO is complementary or substantially complementary to a target pre-mRNA of the dysfunctional gene or disease-causing gene, the target pre-mRNA comprising: - Functionally disabling pseudoexons, including: o 3' splice site at the 5' end; and o 5' splice site at the 3' end.

42. The method of claim 41, wherein the subject is heterozygous for the SNP or homozygous for the SNP, preferably heterozygous.